<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">41814</article-id><article-id pub-id-type="doi">10.7554/eLife.41814</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>A calcium transport mechanism for atrial fibrillation in Tbx5-mutant mice</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-121553"><name><surname>Dai</surname><given-names>Wenli</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4328-9740</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-121532"><name><surname>Laforest</surname><given-names>Brigitte</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-6919-8922</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-97133"><name><surname>Tyan</surname><given-names>Leonid</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9734-7286</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-97132"><name><surname>Shen</surname><given-names>Kaitlyn M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-121540"><name><surname>Nadadur</surname><given-names>Rangarajan D</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-121535"><name><surname>Alvarado</surname><given-names>Francisco J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-0552-9029</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-97130"><name><surname>Mazurek</surname><given-names>Stefan R</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-130587"><name><surname>Lazarevic</surname><given-names>Sonja</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-97131"><name><surname>Gadek</surname><given-names>Margaret</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-121534"><name><surname>Wang</surname><given-names>Yitang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-121536"><name><surname>Li</surname><given-names>Ye</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2969-2894</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-121537"><name><surname>Valdivia</surname><given-names>Hector H</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-37913"><name><surname>Shen</surname><given-names>Le</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-4367-5476</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-131462"><name><surname>Broman</surname><given-names>Michael T</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-107483"><name><surname>Moskowitz</surname><given-names>Ivan P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0014-4963</contrib-id><email>imoskowitz@peds.bsd.uchicago.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-37908"><name><surname>Weber</surname><given-names>Christopher R</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2117-3184</contrib-id><email>christopher.weber@uchospitals.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Pathology</institution><institution>University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Departments of Pediatrics, Pathology, and Human Genetics</institution><institution>University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Department of Medicine, Division of Cardiovascular Medicine</institution><institution>University of Wisconsin-Madison School of Medicine and Public Health</institution><addr-line><named-content content-type="city">Madison</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Medicine</institution><institution>University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution content-type="dept">Section of Neurosurgery, Department of Surgery</institution><institution>University of Chicago</institution><addr-line><named-content content-type="city">Chicago</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="senior_editor"><name><surname>Aldrich</surname><given-names>Richard</given-names></name><role>Senior Editor</role><aff><institution>The University of Texas at Austin</institution><country>United States</country></aff></contrib><contrib contrib-type="editor"><name><surname>Lewis</surname><given-names>Richard S</given-names></name><role>Reviewing Editor</role><aff><institution>Stanford University School of Medicine</institution><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>21</day><month>03</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>8</volume><elocation-id>e41814</elocation-id><history><date date-type="received" iso-8601-date="2018-09-11"><day>11</day><month>09</month><year>2018</year></date><date date-type="accepted" iso-8601-date="2019-02-28"><day>28</day><month>02</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Dai et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Dai et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-41814-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.41814.001</object-id><p>Risk for Atrial Fibrillation (AF), the most common human arrhythmia, has a major genetic component. The T-box transcription factor TBX5 influences human AF risk, and adult-specific <italic>Tbx5</italic>-mutant mice demonstrate spontaneous AF. We report that TBX5 is critical for cellular Ca<sup>2+</sup> homeostasis, providing a molecular mechanism underlying the genetic implication of TBX5 in AF. We show that cardiomyocyte action potential (AP) abnormalities in <italic>Tbx5</italic>-deficient atrial cardiomyocytes are caused by a decreased sarcoplasmic reticulum (SR) Ca<sup>2+</sup> ATPase (SERCA2)-mediated SR calcium uptake which was balanced by enhanced trans-sarcolemmal calcium fluxes (calcium current and sodium/calcium exchanger), providing mechanisms for triggered activity. The AP defects, cardiomyocyte ectopy, and AF caused by TBX5 deficiency were rescued by phospholamban removal, which normalized SERCA function. These results directly link transcriptional control of SERCA2 activity, depressed SR Ca<sup>2+</sup> sequestration, enhanced trans-sarcolemmal calcium fluxes, and AF, establishing a mechanism underlying the genetic basis for a Ca<sup>2+</sup>-dependent pathway for AF risk.</p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.41814.002</object-id><title>eLife digest</title><p>The human heart contains four distinct chambers that work together to pump blood around the body. In individuals with a condition called atrial fibrillation, two of the chambers (known as the atria) beat irregularly and are unable to push all the blood they hold into the other two chambers of the heart. This can cause heart failure and increases the likelihood of blood clots, which may lead to stroke and heart attacks.</p><p>Small molecules called calcium ions play a crucial role in regulating how and when the atria contract by driving electrical activity in heart cells. To contract the atria, a storage compartment within heart cells known as the sarcoplasmic reticulum releases calcium ions into the main compartment of the cells. Calcium ions also enter the cell from the surrounding tissue. As the atria relax, calcium ions are pumped back into the sarcoplasmic reticulum or out of the cell by specific transport proteins.</p><p>Individuals with mutations in a gene called <italic>Tbx5</italic> are more likely to develop atrial fibrillation than other people, but it was not clear how such gene mutations contribute to the disease. Here, Dai, Laforest et al. used mice with a mutation in the <italic>Tbx5</italic> gene to study how defects in <italic>Tbx5</italic> affect electrical activity in heart cells.</p><p>The experiments found that the <italic>Tbx5</italic> gene was critical for calcium ions to drive normal electrical activity in mouse heart cells. Compared with heart cells from normal mice, the heart cells from the mutant mice had decreased flow of calcium ions into the sarcoplasmic reticulum and increased flow of calcium ions out of the cell.</p><p>These findings provide a direct link between atrial fibrillation and the flow of calcium ions in heart cells. Together with previous work, these findings indicate that multiple different mechanisms could lead to atrial fibrillation, but that many of these involve changes in the flow of calcium ions. Therefore, personalized medicine, where clinicians uncover the specific mechanisms responsible for atrial fibrillation in individual patients, may play an important role in treating this condition in the future.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>atrial fibrillation</kwd><kwd>Tbx5</kwd><kwd>SR calcium ATPase</kwd><kwd>calcium handling</kwd><kwd>sodium-calcium exchanger</kwd><kwd>triggered activity</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL126509</award-id><principal-award-recipient><name><surname>Moskowitz</surname><given-names>Ivan P</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>Collaborative Sciences Award</award-id><principal-award-recipient><name><surname>Moskowitz</surname><given-names>Ivan P</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32HL007381</award-id><principal-award-recipient><name><surname>Dai</surname><given-names>Wenli</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL114010</award-id><principal-award-recipient><name><surname>Moskowitz</surname><given-names>Ivan P</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R33 HL123857</award-id><principal-award-recipient><name><surname>Moskowitz</surname><given-names>Ivan P</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>T32GM007281</award-id><principal-award-recipient><name><surname>Dai</surname><given-names>Wenli</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>TBX5-loss associated cardiomyocyte ectopy and atrial fibrillation is prevented by augmentation of SERCA2 activity, establishing a mechanism underlying the genetic basis for a Ca<sup>2+</sup>-dependent pathway for AF risk.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Atrial fibrillation (AF) is the most common arrhythmia in humans, characterized by irregularly irregular atrial electrical activity, resulting in asynchronous atrial contraction. AF is a global problem, affecting more than 33 million people and approximately 25% of Americans over the age of forty (<xref ref-type="bibr" rid="bib39">Nishida and Nattel, 2014</xref>; <xref ref-type="bibr" rid="bib48">Weng et al., 2018</xref>). AF is associated with significant morbidity and mortality due to thromboembolic events, heart failure, and sudden cardiac death. AF also significantly complicates overall health care management, with AF patients costing five times more to treat than patients without AF (<xref ref-type="bibr" rid="bib2">Andrade et al., 2014</xref>). The total annual cost to treat AF patients in the US is on the order of 26 billion dollars (<xref ref-type="bibr" rid="bib39">Nishida and Nattel, 2014</xref>). AF is a highly significant and growing public health concern.</p><p>A genetic basis for AF risk has been described in the last decade. Large community-based cohort studies indicate that heritability provides between 40% and 62% of AF risk (<xref ref-type="bibr" rid="bib39">Nishida and Nattel, 2014</xref>; <xref ref-type="bibr" rid="bib11">Christophersen et al., 2009</xref>). An emerging paradigm describes AF as a multifactorial disease with genetic predisposition that will determine the propensity of secondary clinical insults to cause AF. This model highlights the importance of understanding the molecular mechanisms underlying the genetic predisposition to AF. Genome-wide association studies (GWAS) studies have identified common risk variants and familial mutations at the T-box transcription factor 5 (TBX5) locus that result in increased risk for AF (<xref ref-type="bibr" rid="bib35">McDermott et al., 2008</xref>; <xref ref-type="bibr" rid="bib43">Sinner et al., 2014</xref>). Adult-specific <italic>Tbx5</italic> knockout mice demonstrate primary spontaneous and sustained AF, providing evidence supporting the genetic implication at this locus. GWAS have also implicated multiple genes involved in cardiomyocyte calcium handling, including <italic>Atp2a2</italic>, encoding the sarcolemmal calcium ATPase SERCA2, and <italic>Sln</italic> and <italic>Pln</italic>, encoding direct binding SERCA2 inhibitors sarcolipin and phospholamban, respectively. We have previously demonstrated that these cardiomyocyte calcium control genes are direct TBX5 targets (<xref ref-type="bibr" rid="bib36">Nadadur et al., 2016</xref>). These observations suggested that tight transcriptional control of SERCA2 activity may be central to atrial rhythm robustness and that variation in SERCA2 expression and activity may contribute to AF risk.</p><p>The cellular mechanisms causing the irregular electrical activity in AF are believed to include an abnormal myocardial substrate and formation of an ectopic trigger. Abnormal substrate refers to altered electrical conduction between cardiomyocytes. Ectopic trigger refers to cardiomyocyte ectopy, or initiation of electrical activity at regions outside of the sinoatrial node. Both of these cellular phenomena are observed in <italic>Tbx5</italic> adult-specific mutant mice and have been associated with abnormal cellular calcium handling (<xref ref-type="bibr" rid="bib14">Dobrev, 2010</xref>; <xref ref-type="bibr" rid="bib46">Voigt et al., 2012</xref>; <xref ref-type="bibr" rid="bib47">Voigt et al., 2014</xref>; <xref ref-type="bibr" rid="bib45">Vest et al., 2005</xref>; <xref ref-type="bibr" rid="bib41">Shanmugam et al., 2011</xref>; <xref ref-type="bibr" rid="bib38">Neef et al., 2010</xref>; <xref ref-type="bibr" rid="bib34">Macquaide et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Liang et al., 2008</xref>; <xref ref-type="bibr" rid="bib27">Lenaerts et al., 2009</xref>; <xref ref-type="bibr" rid="bib23">Hove-Madsen et al., 2004</xref>; <xref ref-type="bibr" rid="bib21">Greiser et al., 2011</xref>; <xref ref-type="bibr" rid="bib15">El-Armouche et al., 2006</xref>; <xref ref-type="bibr" rid="bib8">Brundel et al., 1999</xref>). We described the TBX5-dependent gene regulatory network essential for atrial rhythm control and identified downstream ion channels and transporters potentially important to rhythm control (<xref ref-type="bibr" rid="bib36">Nadadur et al., 2016</xref>; <xref ref-type="bibr" rid="bib50">Yang et al., 2017</xref>). Triggered activity in the form of early and delayed afterdepolarizations (EADs and DADs) observed in Tbx5-deficient atrial cardiomyocytes could be rescued by heavy buffering of cytoplasmic calcium (<xref ref-type="bibr" rid="bib36">Nadadur et al., 2016</xref>). <italic>Tbx5</italic>-dependent calcium handling has thereby emerged as a potential mediator of the myocardial physiologic abnormalities resulting in AF.</p><p>We sought to define the Tbx5-dependent cellular mechanisms responsible for abnormal calcium-dependent electrical activity. We found that <italic>Tbx5</italic>-dependent AF is associated with abnormal sarcoplasmic reticulum (SR) calcium uptake due to depressed SERCA2 expression, depressed SERCA function, and increased phospholamban expression. Decreased SR calcium uptake is compensated by increased Ca<sup>2+</sup> extrusion from cardiomyocytes via sodium-calcium exchanger (NCX) current (I<sub>NCX</sub>), which provides a mechanism for TBX5-dependent action potential (AP) prolongation and the propensity for triggered cellular ectopy. In the setting of enhanced NCX mediated Ca<sup>2+</sup> efflux and depressed SR uptake, compensatory increases in L-type calcium current (I<sub>CaL</sub>) balance calcium extrusion to maintain steady state calcium homeostasis. Together these calcium handling alterations contribute to AP prolongation and triggered activity.</p><p>We further demonstrated that calcium handling abnormalities, AP alterations, and triggered activity are all normalized by knockout of phospholamban, which prevents <italic>Tbx5</italic>-dependent AF. These results establish a direct link between depressed SR Ca<sup>2+</sup> sequestration, enhanced NCX activity, and AF. This model suggests that targeting calcium handling pathways may be a treatment approach for a subpopulation of AF patients.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Cytoplasmic calcium is responsible for AP prolongation in <italic>Tbx5</italic>-mutant atrial cardiomyocytes</title><p>We previously reported that <italic>Tbx5</italic>-deficient atrial cardiomyocytes demonstrated AP prolongation and myocardial ectopy. We hypothesized that these defects were caused by cellular calcium handling abnormalities. We therefore surveyed the expression of known calcium handling genes in the adult-specific <italic>Tbx5</italic> knockout model. We assessed gene expression in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> and control <italic>R26<sup>CreERT2</sup></italic> mice at 10 weeks of age following tamoxifen (TM) treatment at 8 weeks of age. Consistent with previous observations, the adult <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> but not control mice developed spontaneous AF, showing an irregularly irregular heartbeat, by telemetric electrocardiogram (ECG) recordings (<xref ref-type="fig" rid="fig1">Figure 1A,B</xref>). As previously shown, APs and [Ca]<sub>i</sub> transients were prolonged in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> (<xref ref-type="fig" rid="fig1">Figure 1C</xref>) (<xref ref-type="bibr" rid="bib36">Nadadur et al., 2016</xref>). We assessed expression of genes important to cellular calcium handling in the left atrium by quantitative PCR (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). mRNA transcripts for RyR2 (<italic>Ryr2</italic>) and SERCA2 (<italic>Atp2a2</italic>), two of the main determinants of sarcoplasmic reticulum (SR) calcium flux, were decreased by 61% and 71% respectively in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> mice compared to <italic>R26<sup>CreERT2</sup></italic> controls (p=0.026 and p=0.001 for <italic>Ryr2</italic> and <italic>Atp2a2</italic> respectively) consistent with previous studies (<xref ref-type="bibr" rid="bib36">Nadadur et al., 2016</xref>). In addition, phospholamban (<italic>Pln</italic>) mRNA expression was increased by 69% in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared to <italic>R26<sup>CreERT2</sup></italic> (p=0.023), which would be expected to further depress SERCA2 activity. There was no significant difference in mRNA expression of the alpha 1C subunit of the L-type calcium channel (<italic>Cacna1c</italic>), the cardiac sodium calcium exchanger (<italic>Ncx1</italic>), or any of the calmodulins 1–3 (<italic>Calm1, Calm2, Calm3</italic>) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). These data are consistent with the hypothesis that the myocardial electrophysiology deficits in the <italic>Tbx5</italic>-deficient AF model may be due to abnormal calcium handling.</p><fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.41814.003</object-id><label>Figure 1.</label><caption><title>Atrial fibrillation in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> mice is associated with altered expression of genes important to cellular calcium handling.</title><p>(<bold>A</bold>) <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> mice developed spontaneous AF as assessed by surface ECG compared to <italic>R26<sup>CreERT2</sup>.</italic> Traces are representative of 15 animals per genotype. (<bold>B</bold>) Poincaré plot shows irregularly irregular rhythm in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>, consistent with AF, compared to normal sinus rhythm in <italic>R26<sup>CreERT2</sup></italic> mice. Poincaré plots are each from one animal, andrepresentative of 15 animals per genotype. (<bold>C</bold>) Simultaneous AP and [Ca]<sub>i</sub> recordings show prolonged AP duration and slowed [Ca<sup>2+</sup>]<sub>i</sub> transient decay in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes compared to <italic>R26<sup>CreERT2</sup></italic>. Recordings are representative of simultaneous [Ca]<sub>i</sub> and E<sub>m</sub> recordings (myocytes/mice; dual E<sub>m</sub> and [Ca]<sub>i</sub> from 5/5 <italic>R26<sup>CreERT2</sup></italic> and 17/5 <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>, E<sub>m</sub> only from 23/9 <italic>R26<sup>CreERT2</sup></italic> and 20/9 <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>, and [Ca]<sub>i</sub> only from 27/6 <italic>R26<sup>CreERT2</sup></italic> and 28/6 <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>). (<bold>D</bold>) Quantitative PCR was performed on RNA isolated from left atrial tissue of 3–5 animals per genotype. mRNA expression of a panel of calcium handling genes potentially important for rhythm regulation was determined. <italic>Ryr2</italic> and <italic>Atp2a2</italic> expression were decreased and <italic>Pln</italic> expression was increased in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> relative to <italic>R26<sup>CreERT2</sup></italic> atria. (***p&lt;0.001, **, p&lt;0.01, *, p&lt;0.05).</p><p><supplementary-material id="fig1sdata1"><object-id pub-id-type="doi">10.7554/eLife.41814.005</object-id><label>Figure 1—source data 1.</label><caption><title>qPCR data for <xref ref-type="fig" rid="fig1">Figure 1D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41814-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.41814.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>PCR primers.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41814-fig1-figsupp1-v1.tif"/></fig></fig-group><p>We examined the relationship between myocardial electrophysiology deficits and calcium flux in <italic>Tbx5</italic>-mutant atria. In steady state, with each cardiomyocyte contraction cycle, calcium entering the cardiomyocyte (L-type calcium channel, I<sub>CaL</sub>) is extruded from the cell (predominantly via inward I<sub>NCX</sub>). Similarly, calcium leaving the SR via RyR2 release or SR leak pathways is taken back up into the SR via SERCA2. We examined the effect of altered TBX5-dependent gene expression on these aspects of cardiomyocyte calcium flux. Given the observed changes in <italic>Ryr2</italic> and <italic>Atp2a2</italic> mRNA abundance, we hypothesized that AP prolongation in <italic>Tbx5</italic> deficient cardiomyocytes was due to calcium handling defects downstream of initial Ca<sup>2+</sup> entry through I<sub>CaL</sub>. To test this, we recorded APs in the presence and absence of the L-type Ca<sup>2+</sup> channel blocker nifedipine. This approach blocks Ca<sup>2+</sup> entry into the cell and indirectly removes the effect of Ca<sup>2+</sup> entry on downstream Ca<sup>2+</sup> handling pathways, including SR Ca<sup>2+</sup> release/reuptake as well as the electrogenic effect of calcium transport out of the cell via inward I<sub>NCX</sub>. 30 μM nifedipine completely inhibited L-type calcium current, preventing Ca<sup>2+</sup> entry or release of SR calcium in control <italic>R26<sup>CreERT2</sup></italic> and <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). In control <italic>R26<sup>CreERT2</sup></italic> atrial cardiomyocytes, the effect of nifedipine on AP duration (APD) was small, with 19 ± 4% shortening of APD at 90% repolarization (APD90) (p=0.008) (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). However, in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes, nifedipine had a profound effect: APD at 50% repolarization (APD50) was shortened by 16 ± 6% and APD90 by 61 ± 6% (p=0.02 and 0.007 respectively) (<xref ref-type="fig" rid="fig2">Figure 2B,C</xref>). Western blot with densitometry analysis for Ca<sub>V</sub>1.2 showed no significant difference in protein expression (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), in line with the qPCR data (<xref ref-type="fig" rid="fig1">Figure 1D</xref>), consistent with no TBX5-driven direct transcriptional regulation of L-type calcium channels. However, peak I<sub>CaL</sub> current was increased 92 ± 34% (p=0.027) in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes compared to control <italic>R26<sup>CreERT2</sup></italic> (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>). The inactivation kinetics at peak I<sub>CaL</sub> were accelerated <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared to control <italic>R26<sup>CreERT2</sup></italic> ( τ = 26.7 ± 3.4 ms <italic>vs</italic>. τ = 40.0 ± 3.0 ms; p=0.05). Steady-state I<sub>CaL</sub> inactivation was unchanged (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). These data suggest that increased I<sub>CaL</sub> may contribute to TBX5-loss associated AP prolongation and EADs. However, nifedipine also blocks SR Ca<sup>2+</sup> release as well as downstream Ca<sup>2+</sup> extrusion pathways, which also affect AP duration. Further, since late AP repolarization is dramatically prolonged (negative to −30 mV where I<sub>CaL</sub> is largely inactive) we hypothesized that <italic>Tbx5</italic>-deficiency disrupts Ca<sup>2+</sup> handling pathways downstream of I<sub>CaL</sub>.</p><fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.41814.006</object-id><label>Figure 2.</label><caption><title>Calcium current blockade dramatically shortened the AP in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes, consistent with the [Ca]<sub>i</sub> dependence of AP prolongation following TBX5 loss.</title><p>(<bold>A</bold>) Representative recording of an AP from <italic>R26<sup>CreERT2</sup></italic> atrial cardiomyocytes before and after 30 µM nifedipine treatment. (<bold>B</bold>) Representative recording of a <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes before and after nifedipine treatment. (<bold>C</bold>) Paired APD properties before and after treatment with 30 µM nifedipine (myocytes/mice; n = 8/3<italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> and n = 6/4 <italic>R26<sup>CreERT2</sup>)</italic>. In <italic>R26<sup>CreERT2</sup></italic> cardiomyocytes, the effect of nifedipine on APD90 was small, but significant 19 ± 4%. A much larger nifedipine effect was observed in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes. APD50 decreased by 16 ± 6% and APD90 decreased by 61 ± 6% in the presence of nifedipine. (<bold>D</bold>) Western blot of atrial tissue in five animals for each genotype showed protein expression for the alpha 1C subunit of the L-type calcium channel (Ca<sub>v</sub>1.2) was unchanged. (normalized to GAPDH) (<bold>E,F</bold>) Representative I<sub>CaL</sub> recordings show Peak L-type calcium current was increased in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes compared to <italic>R26<sup>CreERT2</sup></italic> (<bold>G</bold>) Average IV relationship of L-type calcium current (myocytes/mice; n = 22/7 <italic>R26<sup>CreERT2</sup></italic> and 20/5 <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>). (***p&lt;0.001, **, p&lt;0.01, *, p≤0.05).</p><p><supplementary-material id="fig2sdata1"><object-id pub-id-type="doi">10.7554/eLife.41814.010</object-id><label>Figure 2—source data 1.</label><caption><title>AP and I<sub>CaL</sub> parameters for <xref ref-type="fig" rid="fig2">Figure 2C,G</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><object-id pub-id-type="doi">10.7554/eLife.41814.011</object-id><label>Figure 2—source data 2.</label><caption><title>Western blot for <xref ref-type="fig" rid="fig2">Figure 2D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig2-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41814-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.41814.007</object-id><label>Figure 2—figure supplement 1.</label><caption><title>30 µM Nifedipine blocks L-type calcium current and calcium-induced calcium release in <italic>R26<sup>CreERT2</sup> and Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes.</title></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41814-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.41814.008</object-id><label>Figure 2—figure supplement 2.</label><caption><title>Steady state inactivation of I<sub>CaL</sub> was unchanged in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes.</title><p>(<bold>A</bold>) Protocol used to assess steady state inactivation of I<sub>CaL</sub> (representative trace from <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes) (<bold>B</bold>) Steady state inactivation of I<sub>CaL</sub> was the same in <italic>R26<sup>CreERT2</sup> and Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes. (myocytes/mice; Representative of 4/9 <italic>R26<sup>CreERT2</sup></italic> and 3/10 <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>).</p><p><supplementary-material id="fig2s2sdata1"><object-id pub-id-type="doi">10.7554/eLife.41814.009</object-id><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>I<sub>CaL</sub> parameters for <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig2-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41814-fig2-figsupp2-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Removal of <italic>Tbx5</italic> results in decreased Ca<sup>2+</sup> sparks and RyR2 expression, but no overall reduction in RyR2 open probability</title><p>Because RyR2 is a critically important sarcolemmal calcium extrusion channel and <italic>Ryr2</italic> mRNA was downregulated in <italic>Tbx5</italic>-mutant atria, we investigated the <italic>Tbx5</italic> dependent regulation of RyR2 protein expression and function. RyR2 protein expression was significantly decreased in left atria of <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> mice compared to <italic>R26<sup>CreERT2</sup></italic> mice by western blot (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), consistent with the observed downregulation of <italic>Ryr2</italic> mRNA (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). We hypothesized that decreased RyR2 contributed to abnormal Ca<sup>2+</sup> release from the SR and tested this by measuring local spontaneous RyR2-mediated Ca<sup>2+</sup> release events (Ca<sup>2+</sup> sparks) using confocal linescans (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). The frequency of Ca<sup>2+</sup> sparks in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes was decreased in comparison with <italic>R26<sup>CreERT2</sup></italic> atrial cardiomyocytes at different pacing frequencies from 0 to 2 Hz (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). A decrease in calcium sparks can be due to either decreased RyR2 open probability or a reduced SR calcium load. To differentiate these possibilities, we first examined RyR2 function in the setting of reduced RYR2 expression by performing a [<sup>3</sup>H]-ryanodine binding assay. [<sup>3</sup>H]-ryanodine binding to RyR2 correlates with RyR2 open probability (<xref ref-type="bibr" rid="bib14">Dobrev, 2010</xref>). Despite reduced ryanodine receptor expression, overall ryanodine binding was unchanged over the majority of the physiological range of calcium values, with no shift in calcium sensitivity (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). This observation suggests that the alterations in spark frequency were not due to changes in total RyR2 open probability. Instead, it may be caused by diminished SR Ca<sup>2+</sup> uptake, a SERCA-dependent property.</p><fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.41814.012</object-id><label>Figure 3.</label><caption><title>Spark frequency is reduced in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes.</title><p>(<bold>A</bold>) Western blot from atrial tissue from 10 animals per genotype was used to measure RyR2 expression. RyR2 was significantly decreased in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> atria compared to <italic>R26<sup>CreERT2</sup></italic> atria (normalized to GAPDH). (<bold>B</bold>) Fluo-4 loaded cardiomyocytes demonstrated reduced spark frequency in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared to <italic>R26<sup>CreERT2</sup></italic> atrial cardiomyocytes (representative recordings). (<bold>C</bold>) Spark frequency was reduced at rest and after steady state pacing at different frequencies (myocytes/mice; n = 12/4 <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> and n = 12/3 <italic>R26<sup>CreERT2</sup></italic>). (<bold>D</bold>) Ryanodine binding assay (without normalization) demonstrated no significant difference over the physiologic range of [Ca]<sub>i</sub> in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared to <italic>R26<sup>CreERT2</sup></italic> (<xref ref-type="bibr" rid="bib48">Weng et al., 2018</xref>). Each measure corresponds to an assay performed on pooled atria from 8 to 10 mice with three independent measures per condition (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001).</p><p><supplementary-material id="fig3sdata1"><object-id pub-id-type="doi">10.7554/eLife.41814.013</object-id><label>Figure 3—source data 1.</label><caption><title>Western blot for <xref ref-type="fig" rid="fig3">Figure 3A</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><object-id pub-id-type="doi">10.7554/eLife.41814.014</object-id><label>Figure 3—source data 2.</label><caption><title>Spark analysis for <xref ref-type="fig" rid="fig3">Figure 3C</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig3-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><object-id pub-id-type="doi">10.7554/eLife.41814.015</object-id><label>Figure 3—source data 3.</label><caption><title>Ryanodine binding assay for <xref ref-type="fig" rid="fig3">Figure 3D</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig3-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41814-fig3-v1.tif"/></fig></sec><sec id="s2-3"><title>Adult-specific <italic>Tbx5</italic> deficiency reduces SERCA activity and SR load while increasing sodium-calcium exchanger activity</title><p>We next focused on the balance of diastolic calcium efflux pathways as potential mediators of Ca<sup>2+</sup> mishandling by measuring SR Ca<sup>2+</sup> content and protein expression and function of SERCA2 and NCX1. We observed that SERCA2 protein expression was decreased while NCX1 protein expression was increased in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> in comparison with <italic>R26<sup>CreERT2</sup></italic> atria (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>). To define steady state SR Ca<sup>2+</sup> content, we loaded cardiomyocytes with Fluo-4 AM and paced with a train of field stimuli to achieve a steady state Ca<sup>2+</sup> content, peak Ca<sup>2+</sup> content, and rate of Ca<sup>2+</sup> removal were measured (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>). The [Ca<sup>2+</sup>]<sub>i</sub> transient peaks were unchanged, but [Ca<sup>2+</sup>]<sub>i</sub> transient decay rates, corresponding to SR Ca<sup>2+</sup> uptake and cellular Ca<sup>2+</sup> extrusion, were slowed in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared to <italic>R26<sup>CreERT2</sup></italic> atrial cardiomyocytes (<xref ref-type="fig" rid="fig4">Figure 4E,F</xref>) (<xref ref-type="bibr" rid="bib36">Nadadur et al., 2016</xref>), consistent with defective Ca<sup>2+</sup> removal from the cytosol. We also measured [Ca<sup>2+</sup>]<sub>i</sub> transients in voltage clamp mode using 40 ms square wave voltage clamp pulses from −80 to 0 mV (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Similar to the field stimulation experiments, [Ca<sup>2+</sup>]<sub>i</sub> transient decay rates were slowed, but [Ca<sup>2+</sup>]<sub>i</sub> transient peaks were decreased by 23 ± 4% (p=0.02) in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes compared to <italic>R26<sup>CreERT2</sup></italic>, which suggests that AP prolongation is essential to maintaining peak twitch [Ca<sup>2+</sup>]<sub>i.</sub> The latter experiment is also consistent with depressed SR loads in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared to <italic>R26<sup>CreERT2</sup></italic> atrial myocytes.</p><fig-group><fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.41814.016</object-id><label>Figure 4.</label><caption><title>SERCA function is decreased while NCX function is increased in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes.</title><p>(<bold>A</bold>) Expression of SERCA2 was significantly decreased (normalized to GAPDH) while (<bold>B</bold>) expression of NCX1 was significantly increased in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> atria compared to <italic>R26<sup>CreERT2</sup></italic> atria as measured by western blot in 10 animals per genotype. (normalized to GAPDH) (<bold>C</bold>) Application of Na<sup>+</sup> free caffeine solution after pacing to steady state at 1 Hz provided a measurement of SR load. In the absence of extracellular Na<sup>+</sup>, [Ca<sup>2+</sup>]<sub>i</sub> plateaued at high levels due to negligible role of non-NCX mediated extrusion in <italic>R26<sup>CreERT2</sup></italic> and <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes. Removal of caffeine in the absence of external Na<sup>+</sup> provided a measure of SERCA mediated SR calcium uptake (representative traces). (<bold>D</bold>) Restoration of external Na<sup>+</sup>, in the presence of sustained extracellular caffeine provided a measure of NCX mediated calcium efflux (representative traces). (<bold>E</bold>) The peak of steady state twitch [Ca<sup>2+</sup>]<sub>i</sub> transients was similar but (<bold>F</bold>) tau of [Ca<sup>2+</sup>]<sub>i</sub> decay, determined from twitch [Ca<sup>2+</sup>]<sub>i</sub> transients, was increased in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared to <italic>R26<sup>CreERT2</sup></italic> cardiomyocytes (myocytes/mice; n = 27/6 <italic>R26<sup>CreERT2</sup>, n = 28/6 Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>)</italic>. (<bold>G</bold>) SR load, determined from peak caffeine transients was decreased in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared to R26<sup>CreERT2</sup> cardiomyocytes (myocytes/mice; n = 34/<italic>6 R26<sup>CreERT2</sup>, n = 32/6 Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>). (<bold>H</bold>) SERCA activity, determined from the maximal rate of calcium decay was diminished in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared to <italic>R26<sup>CreERT2</sup></italic> cardiomyocytes (myocytes/mice; n = 29<italic>/3 R26<sup>CreERT2</sup>, n = 32/3 Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>). (<bold>I</bold>) NCX activity (decay slope), was increased at all levels of calcium in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes (myocytes/mice; n = 35<italic>/3 R26<sup>CreERT2</sup>, n = 21/3 Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>)</italic>. (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001).</p><p><supplementary-material id="fig4sdata1"><object-id pub-id-type="doi">10.7554/eLife.41814.019</object-id><label>Figure 4—source data 1.</label><caption><title>Western blot for <xref ref-type="fig" rid="fig4">Figure 4A,B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><object-id pub-id-type="doi">10.7554/eLife.41814.020</object-id><label>Figure 4—source data 2.</label><caption><title>Ca<sup>2+</sup> handling parameters for <xref ref-type="fig" rid="fig4">Figure 4E–H</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig4-data2-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><object-id pub-id-type="doi">10.7554/eLife.41814.021</object-id><label>Figure 4—source data 3.</label><caption><title>NCX activity for <xref ref-type="fig" rid="fig4">Figure 4I</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig4-data3-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41814-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.41814.017</object-id><label>Figure 4—figure supplement 1.</label><caption><title>[Ca<sup>2+</sup>]<sub>i</sub> transients recorded using 40 ms voltage clamp pulses demonstrate 23 ± 4% (p=0.02) reduction in peak calcium in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared to <italic>R26<sup>CreERT2</sup></italic> atrial cardiomyocytes.</title><p>While the decay kinetics of <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> are slowed, there no differences in the initial rate of [Ca<sup>2+</sup>]<sub>i</sub> rise (<italic>R26<sup>CreERT2</sup></italic> rise slope = 107 ± 11 F/F<sub>o</sub>*s; <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> rise slope = 108 ± 18 F/F<sub>o</sub>*s, p=0.96). Average of all myocytes is shown in black with grey indicating standard error of mean (myocytes/mice; n = 5/3 <italic>R26<sup>CreERT2</sup>,</italic> n = 13/5 <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>)</italic>.</p><p><supplementary-material id="fig4s1sdata1"><object-id pub-id-type="doi">10.7554/eLife.41814.018</object-id><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Ca<sup>2+</sup> transients for <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41814-fig4-figsupp1-v1.tif"/></fig></fig-group><p>We hypothesized that decreased SERCA2 expression caused decreased SR load. We examined SERCA activity by synchronizing the opening of RyR2 channels while preventing Ca<sup>2+</sup> extrusion through NCX using caffeine containing, sodium-free, Tyrode solution. This provides a measurement of the maximum release of Ca<sup>2+</sup> into the cytosol from the SR, a measure of the SR Ca<sup>2+</sup> load (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>). SR [Ca<sup>2+</sup>] was reduced by 24 ± 8% (p=0.0005) in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared with <italic>R26<sup>CreERT2</sup></italic> atrial cardiomyocytes (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). SERCA activity was assessed from [Ca<sup>2+</sup>]<sub>i</sub> decay rate after SR release in the absence of external sodium (NCX inactive). Peak SERCA activity was reduced by 31 ± 9% (p=0.006) in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared with <italic>R26<sup>CreERT2</sup></italic> atrial cardiomyocytes (<xref ref-type="fig" rid="fig4">Figure 4C,H</xref>). NCX activity was assessed as the rate of change in [Ca<sup>2+</sup>]<sub>i</sub> decay in Na<sup>+</sup> containing caffeine solution, preventing net SR uptake. Since NCX activity depends on [Ca]<sub>i</sub>, we plotted NCX as a function of the [Ca]<sub>i</sub> signal. NCX activity was ~60% higher in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> in comparison with <italic>R26<sup>CreERT2</sup></italic> atrial cardiomyocytes (<xref ref-type="fig" rid="fig4">Figure 4D,I</xref>). Thus, removal of <italic>Tbx5</italic> causes decreased SR Ca<sup>2+</sup> load and decreased SERCA function, but increased NCX mediated Ca<sup>2+</sup> extrusion. Increased inward NCX activity promotes cardiomyocyte depolarization, providing a mechanism for prolonged APs and increased ectopy in <italic>Tbx5</italic>-mutant atrial cardiomyocytes.</p></sec><sec id="s2-4"><title>Genetic augmentation of SERCA activity and normalization of SR load eliminates susceptibility to AF</title><p>We hypothesized that <italic>Tbx5</italic> deficiency reduces SERCA activity by decreasing SERCA2 protein expression (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) and increasing expression of phospholamban (<italic>Pln</italic>), a negative regulator of SERCA2 (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). If these were the primary causes of decreased SERCA function in <italic>Tbx5</italic>-mutant atria, reduced PLN or PLN phosphorylation (relieving inhibition of SERCA2) would be expected to normalize SERCA function. Western blot analysis showed that PLN expression was significantly increased in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared with <italic>R26<sup>CreERT2</sup></italic> atria (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). In addition, PLN phosphorylation was also increased at serine 16 in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared to <italic>R26<sup>CreERT2</sup></italic>. These data suggest PLN phosphorylation may be a compensatory mechanism in response to decreased SERCA expression and activity, but is insufficient to normalize SERCA function (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Thus, we hypothesized that reduction of <italic>Pln</italic> gene expression would be more effective in restoring SERCA function.</p><fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.41814.022</object-id><label>Figure 5.</label><caption><title>Phospholamban knockout normalized SERCA function in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>.</title><p>(<bold>A</bold>) PLN expression was increased in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> compared to <italic>R26<sup>CreERT2</sup></italic> as measured by western blot with five animals per genotype. PLN expression was normalized to GAPDH. The proportion of PLN S16, but not T17 phosphorylation was also increased (normalized to PLN). (<bold>B</bold>) Representative SR load and SERCA measurements in <italic>R26<sup>CreERT2</sup>, Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>, <italic>Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic>, <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/+</sup>;R26<sup>CreERT2</sup></italic> and <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes were collected as described in <xref ref-type="fig" rid="fig4">Figure 4</xref>. (<bold>C, D</bold>) SR load and SERCA function were significantly higher in <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/+</sup>;R26<sup>CreERT2</sup></italic> and <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic> compared to <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes and comparable to <italic>R26<sup>CreERT2</sup></italic> cardiomyocytes. (<bold>E</bold>) [Ca<sup>2+</sup>]<sub>i</sub> transient peaks were unchanged in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>, <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/+</sup>;R26<sup>CreERT2</sup></italic> and <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic>, but increased in <italic>Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes. (<bold>F</bold>) [Ca<sup>2+</sup>]<sub>i</sub> transient decay rate in <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/+</sup>;R26<sup>CreERT2</sup></italic> and <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes were normalized to that of <italic>R26<sup>CreERT2</sup></italic> cardiomyocytes (myocytes/mice; n = 34/3 <italic>R26<sup>CreERT</sup></italic>, n = 36/3 <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>,</italic> n = 30/3 <italic>Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic>, n = <italic>21</italic>/3 <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/+</sup>;R26<sup>CreERT2</sup>, n = 27</italic>/3 <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-</sup></italic> atrial cardiomyocytes). (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001).</p><p><supplementary-material id="fig5sdata1"><object-id pub-id-type="doi">10.7554/eLife.41814.023</object-id><label>Figure 5—source data 1.</label><caption><title>Western blot for <xref ref-type="fig" rid="fig5">Figure 5A</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig5sdata2"><object-id pub-id-type="doi">10.7554/eLife.41814.024</object-id><label>Figure 5—source data 2.</label><caption><title>Ca<sup>2+</sup> Handling parameters for <xref ref-type="fig" rid="fig5">Figure 5C–F</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig5-data2-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41814-fig5-v1.tif"/></fig><p>We assessed if <italic>Pln</italic> deficiency can affect SERCA function in a dose dependent manner by crossing the <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> with germline <italic>Pln</italic> knockout mice (<italic>Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic>) (<xref ref-type="bibr" rid="bib33">Luo et al., 1994</xref>). We compared SR load and SERCA function in adult-specific <italic>Tbx5; Pln</italic> double mutant mice versus <italic>Tbx5</italic> mutant mice. We measured SR load and SERCA function using caffeine-induced SR release in atrial cardiomyocytes from <italic>R26<sup>CreERT2</sup>, Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>, Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic>, <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/+</sup>;R26<sup>CreERT2</sup></italic> mice, and <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic> mice. Control <italic>Pln</italic> deficient mice (<italic>Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic>) had increased steady state SR load and SERCA activity relative to <italic>R26<sup>CreERT2</sup></italic> (<xref ref-type="fig" rid="fig5">Figure 5C,D</xref>). The decreased SR load and SERCA function observed in <italic>Tbx5</italic> mutant mice (<italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>) was converted to elevated SR load and SERCA function after the removal of <italic>Pln</italic> (<italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-</sup>; R26<sup>CreERT2</sup>)</italic> (<xref ref-type="fig" rid="fig5">Figure 5C,D</xref>). <italic>Pln</italic> loss alone increased peak twitch calcium. However, in the setting of combined <italic>Tbx5;Pln</italic> deficiency, peak twitch calcium and tau twitch were normalized to <italic>R26<sup>CreERT2</sup></italic> values (<xref ref-type="fig" rid="fig5">Figure 5E,F</xref>).</p><p>We next tested the possibility that decreased SERCA function was the mechanism of TBX5-deficiency-driven AP prolongation and triggered activity and that decreased <italic>Pln</italic> may rescue these defects. As we previously showed, <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes exhibited significantly prolonged APs and frequent EADs and DADs compared to <italic>R26<sup>CreERT2</sup></italic> atrial cardiomyocytes (<xref ref-type="fig" rid="fig6">Figure 6A,B</xref>) (<xref ref-type="bibr" rid="bib36">Nadadur et al., 2016</xref>). APs of <italic>Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes were similar to <italic>R26<sup>CreERT2</sup></italic> controls (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). The prolonged AP duration observed <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> was rescued in both <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>+/-</sup>;R26<sup>CreERT2</sup></italic> and <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes (43 ± 10% and 38 ± 5% shorter than <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> respectively; p=0.01, 0.0007) (<xref ref-type="fig" rid="fig6">Figure 6D,E</xref>). Along with normalization of AP duration, we observed significantly fewer EADs and DADs in <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes (<xref ref-type="fig" rid="fig6">Figure 6F</xref>). The data demonstrate the importance of TBX5-driven SERCA activity on cellular electrophysiology and triggered activity in atrial cardiomyocytes and decreased <italic>Pln</italic> rescues both SERCA function and cardiomyocyte electrophysiological abnormalities in <italic>Tbx5</italic>-mutant mice.</p><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.41814.025</object-id><label>Figure 6.</label><caption><title>PLN knockout normalized AP duration and prevented triggered activity in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>.</title><p>Representative APs recorded from (<bold>A</bold>) <italic>R26<sup>CreERT2</sup></italic>, (<bold>B</bold>)<italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>,</italic> (<bold>C</bold>)<italic>Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic>, (<bold>D</bold>)<italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/+</sup>;R26<sup>CreERT2</sup>,</italic> (<bold>E</bold>)<italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-;</sup>R26<sup><italic><sup>CreERT2</sup></italic></sup></italic> atrial cardiomyocytes as described previously in <xref ref-type="fig" rid="fig2">Figure 2</xref>. (<bold>F</bold>) TBX5-loss dependent AP prolongation and frequency of triggered activity was normalized by phospholamban knockout (myocytes/mice: n = 18/7 <italic>R26<sup>CreERT2</sup></italic>, n = 24/12 <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>,</italic> n = 12/5 <italic>Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic>, n = 9/3 <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/+</sup>;R26<sup>CreERT2</sup>, and n = 22</italic>/3 <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic>). (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001).</p><p><supplementary-material id="fig6sdata1"><object-id pub-id-type="doi">10.7554/eLife.41814.026</object-id><label>Figure 6—source data 1.</label><caption><title>AP Parameters for <xref ref-type="fig" rid="fig6">Figure 6F</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-41814-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41814-fig6-v1.tif"/></fig><p>The data above show reducing <italic>Pln</italic> gene dosage rescues calcium handling defects, AP prolongation and triggered activity observed in <italic>Tbx5</italic>-mutant atrial cardiomyocytes. We hypothesized that normalizing these cardiomyocyte cellular defects would reduce AF susceptibility in <italic>Tbx5</italic> knockout mice (<xref ref-type="fig" rid="fig7">Figure 7</xref>). We performed intracardiac burst pacing. All <italic>Tbx5<sup>fl/fl</sup>; R26<sup>CreERT2</sup></italic> mice (6/6) paced into AF, compared to none of the <italic>R26<sup>CreERT2</sup></italic> (0/5) or <italic>Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic> littermate controls (0/7). Consistent with our hypothesis, AF susceptibility was significantly decreased in <italic>Tbx5; Pln</italic> compound knockouts: only 1/11 of <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic> paced into AF (<xref ref-type="fig" rid="fig7">Figure 7F</xref>). Thus, <italic>Tbx5-</italic>deficiency induced AF is due to calcium handling abnormalities, specifically decreased SR load and SERCA activity, and that modulation of the SERCA2 inhibitor, <italic>Pln</italic>, normalized SERCA activity and AF susceptibility caused by <italic>Tbx5</italic> loss.</p><fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.41814.027</object-id><label>Figure 7.</label><caption><title>PLN deficiency protected against TBX5-loss associated AF Intra-atrial pacing was used to induce AF.</title><p>Representative intracardiac atrial electrogram recordings and corresponding surface ECG are shown from (<bold>A</bold>) <italic>R26<sup>CreERT2</sup></italic>, (<bold>B</bold>)<italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>,</italic> (<bold>C</bold>)<italic>Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic>, (<bold>D</bold>)<italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/+</sup>;R26<sup>CreERT2</sup>,</italic> (<bold>E</bold>)<italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic> atrial cardiomyocytes. A, atrial electrical signal; V, far field ventricular electrical signal. (<bold>F</bold>) AF was reproducibly demonstrated in 6/6 <italic>Tbx5</italic> knockouts in contrast to 1/11 <italic>Pln/Tbx5</italic> double knockouts, indicating rescue of atrial arrhythmogenesis. P values were determined by Fisher’s exact test (n = 5 <italic>R26<sup>CreERT2</sup></italic>, n = 6 <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup>,</italic> n = 7 <italic>Pln<sup>-/-</sup>;R26<sup>CreERT2</sup></italic>, and n = 5 <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/+</sup>;R26<sup>CreERT2</sup>, n</italic> = 11 <italic>Tbx5<sup>fl/fl</sup>;Pln<sup>-/-</sup></italic> mice).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41814-fig7-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>AF initiation has been linked to calcium handling abnormalities in computational and in vivo disease models (<xref ref-type="bibr" rid="bib20">Grandi et al., 2011</xref>; <xref ref-type="bibr" rid="bib22">Heijman et al., 2014</xref>). Ectopic or triggered activity in the form of EADs and DADs are often due to calcium handling abnormalities that increase NCX activity and promote AF initiation (<xref ref-type="bibr" rid="bib22">Heijman et al., 2014</xref>). However, the mechanism underlying genetic predispositions for AF remain poorly understood. Genetic variants and mutations at the <italic>Tbx5</italic> locus are associated with increased risk for human AF and <italic>Tbx5</italic>-mutant mice show both spontaneous and burst pacing-induced AF (<xref ref-type="bibr" rid="bib36">Nadadur et al., 2016</xref>). We report a calcium transport mechanism for <italic>Tbx5</italic>-dependent ectopic activity. We show that TBX5 is a critical regulator of SERCA-mediated SR calcium handling and that <italic>Tbx5</italic>-deficient mice have increased NCX-mediated Ca<sup>2+</sup> extrusion, balanced by increased I<sub>CaL</sub> mediated Ca<sup>2+</sup> influx. These calcium handling abnormalities provide a mechanism explaining the frequent triggered activity observed after TBX5 knockout. We show that decreasing phospholamban dosage can normalize TBX5-loss associated cellular calcium handling abnormalities, shorten AP duration, prevent triggered activity, and diminish AF susceptibility.</p><sec id="s3-1"><title>Decreased SERCA activity and SR load in TBX5-loss associated atrial fibrillation</title><p>We and others have hypothesized that ectopic triggers of AF can be due to abnormal atrial calcium handling (<xref ref-type="bibr" rid="bib21">Greiser et al., 2011</xref>; <xref ref-type="bibr" rid="bib4">Bers and Grandi, 2011</xref>). Here we define this relationship in a model of spontaneous AF. We analyzed the major calcium transport pathways in atrial myocytes and demonstrated that the critical calcium handling deficit associated with <italic>Tbx5-</italic>loss is depressed SERCA-mediated SR calcium uptake. We report significant reduction of SERCA2 protein expression and function, consistent with human paroxysmal or chronic AF (<xref ref-type="bibr" rid="bib46">Voigt et al., 2012</xref>; <xref ref-type="bibr" rid="bib47">Voigt et al., 2014</xref>; <xref ref-type="bibr" rid="bib15">El-Armouche et al., 2006</xref>; <xref ref-type="bibr" rid="bib8">Brundel et al., 1999</xref>).</p><p>The mechanism causing cardiomyocyte depolarizations from depressed SERCA activity must be indirect, given that SERCA2 is localized to the intracellular SR membrane and therefore does not directly contribute to membrane potential itself. Instead, slowed SR calcium uptake from depressed SERCA activity provides higher cytosolic calcium driving force for calcium extrusion from the cell via electrogenic inward I<sub>NCX</sub>.</p></sec><sec id="s3-2"><title>Increased NCX activity in <italic>Tbx5</italic>- mutant atrial cardiomyocytes drives ectopic activity</title><p>We demonstrate increased NCX1 protein expression with <italic>Tbx5</italic> knockout, a finding also observed in human and other animal models of AF (<xref ref-type="bibr" rid="bib38">Neef et al., 2010</xref>; <xref ref-type="bibr" rid="bib27">Lenaerts et al., 2009</xref>; <xref ref-type="bibr" rid="bib21">Greiser et al., 2011</xref>; <xref ref-type="bibr" rid="bib15">El-Armouche et al., 2006</xref>). Since protein expression, electrochemical driving force, and allosteric calcium regulation can all affect amplitude of inward I<sub>NCX</sub> (<xref ref-type="bibr" rid="bib6">Blaustein and Lederer, 1999</xref>), we measured NCX activity following loss of <italic>Tbx5</italic>. NCX activity was significantly increased at all levels of calcium (<xref ref-type="fig" rid="fig4">Figure 4I</xref>). Thus, increased NCX function coupled with prolonged [Ca<sup>2+</sup>]<sub>i</sub> transients, drives increased inward I<sub>NCX</sub>, providing additional depolarizing current during the AP, contributing to its prolongation. While increased NCX function may partially compensate for the depressed SERCA function to bring down calcium levels, it may also promote calcium-induced DADs in the setting of inappropriately timed SR calcium release events. Previous modeling in ventricular cardiomyocytes predicted countervailing functions of SERCA and NCX (<xref ref-type="bibr" rid="bib28">Li et al., 2011</xref>), which we observed in <italic>Tbx5</italic> knockout mice. Our data further support that DADs, which are classically thought to relate to SR calcium overload can still occur with depressed SR loads in the appropriate context of depressed SERCA and elevated NCX function (<xref ref-type="bibr" rid="bib46">Voigt et al., 2012</xref>).</p><p>Modeling suggests that compensatory increases in L-type calcium current in the setting of depressed SERCA function could be required to maintain systolic and diastolic calcium levels (<xref ref-type="bibr" rid="bib28">Li et al., 2011</xref>). In line with the modeling, we observed enhanced peak I<sub>CaL</sub> with loss of <italic>Tbx5</italic>. This may account for early AP prolongation as well as EADs. It is interesting that peak [Ca]<sub>i</sub> is depressed using controlled square wave voltage clamp pulses (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>), which suggests that 40 ms is insufficient to maintain calcium entry in <italic>Tbx5</italic> knockout, even in the setting of enhanced I<sub>CaL</sub>. However, in the setting of AP prolongation (<xref ref-type="fig" rid="fig2">Figure 2E–G</xref>) peak twitch calcium levels are maintained. Additionally, the increase in calcium entering the cell through I<sub>CaL</sub> during the AP would be expected to balance a net increase in NCX mediated calcium extrusion (<xref ref-type="fig" rid="fig4">Figure 4I</xref>), a requirement for steady state [Ca<sup>2+</sup>]<sub>i</sub> homeostasis. However, our observations that L-type calcium channel expression is TBX5-independent (<xref ref-type="fig" rid="fig1">Figures 1D</xref> and <xref ref-type="fig" rid="fig2">2D</xref>) and that genetically targeting only the Ca<sup>2+</sup> efflux pathways in our model is sufficient to restore normal electrical activity (<xref ref-type="fig" rid="fig5">Figures 5</xref>–<xref ref-type="fig" rid="fig7">7</xref>) suggest that the I<sub>CaL</sub> change is not a primary TBX5-dependent effect. Furthermore, although I<sub>CaL</sub> is increased, it quickly inactivates in TBX5 knockout cardiomyocytes (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Together with our observation that nifedipine normalizes the APD, this supports that enhanced calcium entry impacts APD via secondary [Ca]<sub>i</sub> dependent mechanisms.</p></sec><sec id="s3-3"><title>TBX5 loss results in reduced RyR2 expression</title><p>In addition to identifying the role of altered NCX and SERCA function, we assessed the importance of TBX5-driven RyR2 expression. <italic>RYR2</italic> is a known susceptibility locus for AF and <italic>RYR2</italic> mutations are correlated with AF (<xref ref-type="bibr" rid="bib16">Fatkin et al., 2017</xref>; <xref ref-type="bibr" rid="bib13">Di Pino et al., 2014</xref>). We observed that RyR2 protein expression was significantly depressed following <italic>Tbx5</italic> loss . Defective RyR2 function has also been associated with AF (<xref ref-type="bibr" rid="bib45">Vest et al., 2005</xref>; <xref ref-type="bibr" rid="bib25">King et al., 2013</xref>). Despite TBX5-dependent RyR2 expression, the ryanodine binding assay (<xref ref-type="bibr" rid="bib49">Xu et al., 1998</xref>) suggested that RyR2 function is generally preserved over the physiologic range of calcium in <italic>Tbx5</italic>-mutant atria (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). This suggests a compensatory mechanism must occur allowing for preserved RyR2 open probability in the setting of depressed protein expression. For example, CaMKII is a potential regulator of RyR2 function which could increase the open probability and thereby increase steady leakage or favor spontaneous local Ca<sup>2+</sup> release events from the SR (<xref ref-type="bibr" rid="bib45">Vest et al., 2005</xref>; <xref ref-type="bibr" rid="bib38">Neef et al., 2010</xref>; <xref ref-type="bibr" rid="bib19">Fischer et al., 2015</xref>) in <italic>Tbx5</italic>-deficient mice. In line with such compensation, we could not detect any differences in the calcium rise kinetics during controlled square wave voltage clamp pulses (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Nevertheless, RyR2 compensation in the setting of reduced expression could contribute to abnormal triggered activity in the setting of <italic>Tbx5</italic> loss, and is an important topic for further investigation.</p></sec><sec id="s3-4"><title>Abnormalities of the TBX5/SERCA2/PLN regulatory axis drive AF formation</title><p>We found that depressed SERCA function in TBX5 knockout was completely normalized with heterozygous or homozygous phospholamban knockout, which normalized AP duration, decreased frequency of afterdepolarizations, and reduced AF inducibility. This finding demonstrates the importance of SERCA2 to the pathophysiology of AF in the <italic>Tbx5-</italic>loss model. While phospholamban has been associated with AF by GWAS (<xref ref-type="bibr" rid="bib16">Fatkin et al., 2017</xref>; <xref ref-type="bibr" rid="bib17">Federico et al., 2017</xref>), its functional role is less clear. Although PLN is predominantly found in the ventricle (<xref ref-type="bibr" rid="bib5">Bhupathy et al., 2007</xref>), we showed not only its expression is increased in the atria in the context of <italic>Tbx5</italic> loss, but also PLN participates in rheostatic control of SERCA activity in the atria, which is sufficient to protect against AF inducibility (<xref ref-type="fig" rid="fig5">Figures 5</xref>–<xref ref-type="fig" rid="fig7">7</xref>). Our findings are further supported by patient studies. For example, in patients who experience post-operative AF, SERCA2 is significantly decreased in the atrial tissue (<xref ref-type="bibr" rid="bib51">Zaman et al., 2016</xref>), but those with PLN mutations have decreased AF susceptibility in the context of arrhythmogenic right ventricular cardiomyopathy (<xref ref-type="bibr" rid="bib7">Bourfiss et al., 2016</xref>). Thus, AF is a heterogeneous disease and there can be variability in how the calcium handling proteins are expressed (<xref ref-type="bibr" rid="bib12">Dai et al., 2016</xref>) in different disease settings. The genetic background of an individual may be a critical determinant of how calcium handling moieties are disrupted to result in AF.</p><p>In summary, the most important features of the <italic>Tbx5</italic>-dependent SERCA2 and PLN regulatory axis are reduced SR uptake and load (<xref ref-type="fig" rid="fig8">Figure 8</xref>). In this setting, enhanced inward I<sub>NCX</sub> and I<sub>CaL</sub> contributes to AP prolongation, and, more importantly, to cardiomyocyte ectopy. Finally, we demonstrate PLN as a potential means to augment SERCA function, restoring normal atrial myocyte electrical activity and normal sinus rhythm in <italic>Tbx5</italic> knockout mice. Thus, the <italic>Tbx5</italic> knockout model represents an excellent system to study pharmacologic rescue of SERCA activity, prevention of cardiomyocyte ectopy, and AF.</p><fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.41814.028</object-id><label>Figure 8.</label><caption><title>Model of TBX5-dependent calcium regulation in atrial cardiomyocytes.</title><p>(<bold>A</bold>) Excitation-contraction coupling of atrial cardiomyocytes is achieved through regulation of intracellular calcium handling. (<bold>B</bold>) Adult-specific <italic>Tbx5</italic> knockout leads to decreased expression of SERCA2 and increased expression of PLN, leading to decreased SR Ca<sup>2+</sup> load. In addition, removal of <italic>Tbx5</italic> is associated with increased NCX1 expression and activity, thereby increasing Ca<sup>2+</sup> extrusion, which is balanced by increased L-type calcium entry. (<bold>C</bold>) Combined <italic>Tbx5/Pln</italic> knockout relieves repression of SERCA2. This results in normalization of SERCA activity and rescue of cardiomyocyte ectopy, triggered activity, and AF observed with <italic>Tbx5</italic> deficiency.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-41814-fig8-v1.tif"/></fig></sec><sec id="s3-5"><title>Broader implications for clinical treatment of AF</title><p>AF has become an increasingly common cause of morbidity and mortality, underlying over one-third of stroke cases and significantly increases the risk for heart failure (<xref ref-type="bibr" rid="bib39">Nishida and Nattel, 2014</xref>). Consequently, AF poses a significant socioeconomic burden. AF does not always exist in isolation, but rather in conjunction with other predisposing factors such as obesity, thyroid hormone alterations, or heart failure. Interestingly, disruptions in calcium handling proteins such as the SERCA2-PLN regulatory axis are implicated as predisposing factors. In AF compounded by heart failure, decreased SERCA2 and phosphorylated PLN, and increased NCX1 expression were observed (<xref ref-type="bibr" rid="bib32">Lugenbiel et al., 2015</xref>). Decrease in phosphorylated PLN coupled with an increase in total PLN has been found in animal models of obesity, potentially increasing risk of AF (<xref ref-type="bibr" rid="bib31">Lima-Leopoldo et al., 2014</xref>; <xref ref-type="bibr" rid="bib30">Lima-Leopoldo et al., 2008</xref>). These findings suggest a need to evaluate an individual’s genetic background as well as changes in calcium handling proteins when considering predisposing factors for AF.</p><p>Currently, there are few effective and targeted AF therapies, in part due to an incomplete understanding of the mechanisms underlying AF. Recent studies of specific genetic loci for AF susceptibility have opened new opportunities to identify specific mechanisms at play in subpopulations of AF patients. Understanding these specific mechanisms may facilitate more effective personalized therapies to target specific atrial Ca<sup>2+</sup> handling abnormalities. Our data is consistent with the knowledge that pharmacologic regulators of NCX1 or SERCA2 may normalize defects in cellular calcium handling in the atrium (<xref ref-type="bibr" rid="bib14">Dobrev, 2010</xref>; <xref ref-type="bibr" rid="bib24">Jost et al., 2013</xref>; <xref ref-type="bibr" rid="bib37">Nagy et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">Ferrandi et al., 2013</xref>; <xref ref-type="bibr" rid="bib40">Parikh et al., 2012</xref>). For example, a selective NCX1 inhibitor, ORM-10103, was shown to prevent cellular Ca<sup>2+</sup> handling abnormalities in ischemic ventricular cardiomyocytes, possibly by limiting calcium entry through outward I<sub>NCX</sub> (<xref ref-type="bibr" rid="bib24">Jost et al., 2013</xref>; <xref ref-type="bibr" rid="bib26">Kormos et al., 2014</xref>). The benefit of NCX inhibition might also be considered in human cases of AF with increased NCX activity. Further, resveratrol, which increases SERCA2 activity, has been shown to decrease AF, suggesting that targeting SERCA2 activity may be a viable therapeutic approach (<xref ref-type="bibr" rid="bib3">Bai et al., 2016</xref>; <xref ref-type="bibr" rid="bib10">Chong et al., 2015</xref>). In addition to providing specific insight into treating TBX5-loss associated AF, our findings may be more broadly applied. These data suggest that pharmacological treatment of AF may be improved by assessing for a defect in the TBX5-SERCA2-PLN axis followed by specifically targeting the defect to restore normal cardiomyocyte electrical activity. We expect this work and continued efforts to uncover mechanisms responsible for AF in subpopulations of patients will play a key role in advancing personalized therapeutics for AF.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type (species) <break/>or resource</th><th valign="top">Designation</th><th valign="top">Source or <break/>reference</th><th valign="top">Identifiers</th><th valign="top">Additional <break/>information</th></tr></thead><tbody><tr><td valign="top">Genetic reagent <break/>(M. musculus)</td><td valign="top"><italic>Tbx5<sup>fl/fl</sup></italic> (<italic>Tbx5</italic><sup>tm1Jse</sup>)</td><td valign="top">PMID: 11572777, 27582060</td><td valign="top">MGI:2387850</td><td valign="top">Dr. Jonathan G Seidman (Harvard)</td></tr><tr><td valign="top">Genetic reagent <break/>(M. musculus)</td><td valign="top"><italic>Pln<sup>-/-</sup></italic> (<italic>Pln</italic><sup>tm1Egk</sup>)</td><td valign="top">PMID: 8062415</td><td valign="top">MGI:2158357</td><td valign="top">Dr. Evangelia Kranias (University of Cincinnati)</td></tr><tr><td valign="top">Genetic reagent <break/>(M. musculus)</td><td valign="top"><italic>Rosa26<sup>CreERT2</sup></italic>(<italic>Gt(ROSA)26Sor</italic><sup>tm1(cre/ERT2)Tyj</sup>)</td><td valign="top">PMID: 17251932, 27582060</td><td valign="top">MGI:3790674</td><td valign="top">Dr. Tyler Jacks (Massachusetts Insititute of Technology)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse anti-RyR2</td><td valign="top">ThermoFisher</td><td valign="top">Cat. #: MA3-925</td><td valign="top">WB (1:2000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse anti-SERCA2</td><td valign="top">ThermoFisher</td><td valign="top">Cat. #: MA3-919</td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse anti-NCX</td><td valign="top">ThermoFisher</td><td valign="top">Cat. #: MA3-926</td><td valign="top">WB (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse anti-PLN</td><td valign="top">Badrilla</td><td valign="top">Cat. #: A010-14</td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit anti-pT17-PLN</td><td valign="top">Badrilla</td><td valign="top">Cat. #: A010-13</td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit anti-pS16-PLN</td><td valign="top">Badrilla</td><td valign="top">Cat. #: A010-12</td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit anti-Cav1.2</td><td valign="top">Alomone</td><td valign="top">Cat. #: ACC-003</td><td valign="top">WB (1:200)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Mouse anti-GAPDH</td><td valign="top">Millipore</td><td valign="top">Cat. #: MAB374</td><td valign="top">WB (1:10000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-mouse-HRP</td><td valign="top">Thermofisher</td><td valign="top">Cat. #: 31437</td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-rabbit-HRP</td><td valign="top">Thermofisher</td><td valign="top">Cat. #: 31463</td><td valign="top">WB (1:5000)</td></tr><tr><td valign="top">Chemical <break/>compound, drug</td><td valign="top">Fluo-4 AM</td><td valign="top">Thermofisher</td><td valign="top">Cat. #: 14201</td><td valign="top">10 µM x 20 min</td></tr><tr><td valign="top">Chemical <break/>compound, drug</td><td valign="top">Nifedipine</td><td valign="top">Sigma</td><td valign="top">Cat. #: N7634</td><td valign="top">30 µM</td></tr><tr><td valign="top">Chemical <break/>compound, drug</td><td valign="top">Collagenase Type 2</td><td valign="top">Worthington Biochemical</td><td valign="top">Cat. # LS004177</td><td valign="top">1 g/L</td></tr><tr><td valign="top">Chemical <break/>compound, drug</td><td valign="top">Tamoxifen</td><td valign="top">MP Biomedicals</td><td valign="top">Cat#: 156738</td><td valign="top">2 mg/injection x three doses</td></tr><tr><td valign="top">Chemical <break/>compound, drug</td><td valign="top">Laminin</td><td valign="top">Invitrogen</td><td valign="top">Cat. #: 2039175</td><td valign="top">0.5 mg/ml</td></tr><tr><td valign="top">Chemical <break/>compound, drug</td><td valign="top">[3H]ryanodine</td><td valign="top">PerkinElmer</td><td valign="top">Cat. #: NET950250UC</td><td valign="top"/></tr><tr><td valign="top">Chemical <break/>compound, drug</td><td valign="top">TRIzol</td><td valign="top">Invitrogen</td><td valign="top">Cat. #: 15596026</td><td valign="top"/></tr><tr><td valign="top">Chemical <break/>compound, drug</td><td valign="top">Ryanodine</td><td valign="top">MP Biomedicals</td><td valign="top">SKU #:0215377001</td><td valign="top"/></tr><tr><td valign="top">Chemical <break/>compound, drug</td><td valign="top">Caffeine</td><td valign="top">Sigma</td><td valign="top">Cat. #: C0750</td><td valign="top">10 mM</td></tr><tr><td valign="top">Software, <break/>algorithm</td><td valign="top">Clampex/Clampfit Data acquisition and analysis</td><td valign="top">Molecular Devices</td><td valign="top">Version 10.3.2.1</td><td valign="top"/></tr><tr><td valign="top">Software, <break/>algorithm</td><td valign="top">LabChart for electrophysiology <break/>studies</td><td valign="top">ADInstruments</td><td valign="top">Version 5 and 8</td><td valign="top"/></tr><tr><td valign="top">Software, <break/>algorithm</td><td valign="top">Buffering analyses using MaxChelator</td><td valign="top">Stanford</td><td valign="top">WEBMAXCLITE v1.15</td><td valign="top">Chris Patton, Stanford University</td></tr><tr><td valign="top">Software, <break/>algorithm</td><td valign="top">Western Blot quantification ImageJ</td><td valign="top">NIH</td><td valign="top">Version 1.48</td><td valign="top"/></tr><tr><td valign="top">Software, <break/>algorithm</td><td valign="top">Hierarchical Statistical technique using R</td><td valign="top">R Core Team</td><td valign="top">Script from PMID: 29016722</td><td valign="top">Ken Macleod, Imperial College London</td></tr><tr><td valign="top">Commercial <break/>Assay or Kit</td><td valign="top">qScript cDNA synthesis kit</td><td valign="top">Quanta</td><td valign="top"/><td valign="top"/></tr><tr><td valign="top">Commercial <break/> Assay or Kit</td><td valign="top">Power SYBR Green PCR Master Mix</td><td valign="top">Applied Biosystems</td><td valign="top"/><td valign="top"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Generation of mice</title><p>The <italic>Tbx5<sup>fl/fl</sup></italic>, <italic>Pln<sup>-/-</sup></italic> and <italic>Rosa26<sup>CreERT2</sup></italic> lines have all been previously described and were kept in a mixed genetic background (<xref ref-type="bibr" rid="bib33">Luo et al., 1994</xref>; <xref ref-type="bibr" rid="bib9">Bruneau et al., 2001</xref>; <xref ref-type="bibr" rid="bib44">Ventura et al., 2007</xref>). Double knockout mice were generated by crossing <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> mice with germline <italic>Pln<sup>-/-</sup></italic> mice. After two generations, we obtained <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> mice with either loss of one (<italic>Pln<sup>+/-</sup></italic>) or both (<italic>Pln<sup>-/-</sup></italic>) copies of <italic>Pln</italic>. All experiments were done using age- and genetic strain-matched littermate controls. Tamoxifen was administered for three consecutive days at a dose of 0.167 mg/kg body weight by intraperitoneal injection at 6–10 weeks of age, as previously described (<xref ref-type="bibr" rid="bib36">Nadadur et al., 2016</xref>). All experiments were performed in accordance to The University of Chicago Institutional Animal Care and Use Committee (IACUC) approved protocol.</p></sec><sec id="s4-2"><title>ECG recordings</title><p>8-to 10- week-old mice were anesthetized using isoflurane, and telemetry transmitters (ETA-F10, Data Science International) were implanted in the back with leads tunneled to the right upper and left lower thorax, as previously described (Wheeler MT et al., JCI 2004). Baseline recordings were obtained for 24 hr after a post-implant recovery period of one day. ECG data was analyzed using LabChart 8 (AD Instruments).</p></sec><sec id="s4-3"><title>Intracardiac electrophysiology studies</title><p>Detailed protocols for intracardiac electrograms have been previously described (<xref ref-type="bibr" rid="bib36">Nadadur et al., 2016</xref>). Briefly, 8- to 10- week-old mice were anesthetized with isoflurane and a vertical skin cut-down at the right jugular vein was performed. A 1.1 F octapolar catheter (EPR-800, Millar Instruments) was advanced in the right jugular vein to perform electrical stimulation. The catheter was connected to ADI BioAmp and PowerLab apparatus and signals were recorded using LabChart Software (ADInstruments). Atrial induction pacing was performed using burst pacing and the presence of at least three cycles of atrial tachycardia or fibrillation at least twice was considered positive.</p></sec><sec id="s4-4"><title>[Ca<sup>2+</sup>]<sub>i</sub> transient measurement</title><p>Langendorff perfusion with 2 mg/mL of Collagenase Type 2 (Worthington Biochemical) at 5 ml/min was used to isolate atrial cardiomyocytes. Cardiomyocytes were then plated on laminin coated glass bottom dishes for 30 min prior to incubation with 10 µM Fluo-4/AM (Molecular Probes/Invitrogen) in normal Tyrode’s solution containing (in mM): 140 NaCl, 4 KCl, 10 glucose, 10 HEPES, and 1 MgCl<sub>2</sub>, 1 CaCl<sub>2</sub> pH 7.4 using NaOH for 20 min at room temperature. Cells were perfused with prewarmed Tyrode for 10 min prior to imaging. Imaging was performed on an Olympus microscope with a 20x objective lens, a LAMBDA DG-4 power source with 488 nm excitation and 515 nm emission filters and a PMT (photomultiplier tube) to record whole cell signal. Electrical field stimulation (Grass stimulator; Astro-Med) was performed at 1 Hz. SERCA and NCX measurements were performed by flowing sodium free Tyrode with 10 mM caffeine followed by sodium free Tyrode alone or Tyrode with caffeine respectively. Cells were returned to normal Tyrode in both cases at the end of the recording. [Ca<sup>2+</sup>]<sub>i</sub> transients are presented as total fluorescence intensity normalized to resting fluorescence (F/F<sub>0</sub>) obtained from steady-state resting conditions before field stimulation. [Ca<sup>2+</sup>]<sub>i</sub> transients and sparks were acquired in line-scan mode (3 ms per scan; pixel size 0.12 µm) using a Zeiss confocal microscope.</p></sec><sec id="s4-5"><title>Whole-cell electrophysiological recordings</title><p>APs and voltage clamp recordings were recorded using standard ruptured patch protocol (<xref ref-type="bibr" rid="bib36">Nadadur et al., 2016</xref>). We used current clamp mode with 0.5 nA ×2 ms current clamp pulses to measure APs. Voltage clamp mode was used to measure capacitance transients and to study [Ca<sup>2+</sup>]<sub>i</sub> transients with fixed duration depolarizations. Cardiomyocytes are kept at 37°C and perfused with Tyrode solution (140 NaCl, 4 KCl, 1 MgCl<sub>2</sub>, 1 CaCl<sub>2</sub>, 10 HEPES, 10 Glucose, and pH 7.4 with NaOH). Internal pipette solution composition was (in mM): 20 KCl, 100 K-glutamate, 10 HEPES, 5 MgCl<sub>2</sub>, 10 NaCl, 5 Mg-ATP, 0.3 Na-GTP. Patch pipettes (World Precision Instruments) were pulled to have a mean resistance of 3.5–5 MΩ. An Ag–AgCl pellet and 3M KCl agar bridge was used to ground the bath. Liquid junction potentials, were always corrected after cell rupture.</p><p>External solution for I<sub>CaL</sub> contained (in mM): 120 Tetraethylammonium-chloride, 10 CsCl, 10 Glucose, 10 HEPES, 1.5 MgCl<sub>2</sub>, 1 CaCl<sub>2</sub>, pH 7.4 with CsOH. Internal pipette solution contained (in mM): 100 Cs-methanesulfonate, 30 CsCl, 10 HEPES 5 EGTA, 2 MgCl<sub>2</sub>, 5 Mg-ATP, pH 7.2 with CsOH. I<sub>CaL</sub> was recorded during 200 ms voltage clamp pulses from a holding potential of −40 mV to test potentials ranging from −40 to 60 mV, with pulses applied every 2 s in 5 mV increments. Peak current amplitudes were normalized to the cell capacitance (C<sub>m</sub>) and presented as current density (A/F). Steady-state inactivation of I<sub>CaL</sub> was investigated using two-pulse protocol. Holding potential was −80 mV. The first pulse depolarized membrane from −60 to 20 mV with 10 mV increments during 500 ms, the second pulse depolarized the membrane to 10 mV for 50 ms. The inactivation curves were fit to a Boltzmann distribution.</p><p>Acquisition was performed using an Axopatch-200B amplifier connected to a Digidata1550A acquisition system (Axon Instruments, Foster City, CA, USA). In recording filtering at 2 kHz was performed using the amplifier Bessel and sampled at 10 kHz. Analysis was performed using pCLAMP10 (Axon Instruments) and a home written analysis code.</p></sec><sec id="s4-6"><title>Western blots</title><p>Atrial tissue was collected and homogenized as described previously (<xref ref-type="bibr" rid="bib1">Alvarado et al., 2017</xref>), in a buffer containing 0.9% NaCl, 10 mM Tris-HCl pH 6.8, 20 mM NaF and protease inhibitors. Equal amounts of protein, as determined by Bradford assay, were loaded. 50 µg of tissue homogenate, in Laemmli buffer, was separated by SDS-PAGE in 4–20% TGX or AnyKD precast gels (Bio-Rad). Proteins were transferred to PVDF membrane using the iblot2 transfer system (ThermoFisher) or wet transfer. Primary antibodies were as follows: anti-RyR2 (1:2000; MA3-925, ThermoFisher), SERCA2 (1:1000; MA3-919, ThermoFisher), NCX (1:1000; MA3-926, ThermoFisher), PLN (1:5000; A010-14, Badrilla), pT17-PLN (1:5000; A010-13, Badrilla), pS16-PLN (1:5000; A010-12, Badrilla), Cav1.2 (1:200; ACC-003, Alomone), GAPDH (1:10000; MAB374, Millipore). Secondary antibodies were: goat anti-mouse-HRP (1:5000; 31437, ThermoFisher) or goat anti-rabbit-HRP (1:5000; 31463, ThermoFisher). Secondary antibody concentrations were 5x higher when using the ibind Flex system. SuperSignal ECL reagent (ThermoFisher) was used to develop membranes followed by imaging with a ChemiDoc MP apparatus (Bio-Rad). Band intensities were quantified with the ImageLab software (Bio-Rad) or using ImageJ (NIH).</p></sec><sec id="s4-7"><title>[<sup>3</sup>H]Ryanodine binding assay</title><p>Binding assays were carried out following a protocol previously described (<xref ref-type="bibr" rid="bib17">Federico et al., 2017</xref>). Binding mixtures contained 100 µg of protein from homogenates prepared from pooled atria (5–7 mice), 0.2 M KCl, 20 mM Hepes (pH 7.4), 6.5 nM [<sup>3</sup>H]ryanodine (PerkinElmer), 1 mM EGTA and enough CaCl<sub>2</sub> to set free [Ca<sup>2+</sup>] between 10 nM (pCa<sup>2+</sup> 8) and 100 µM (pCa<sup>2+</sup> 4). The ratio between Ca<sup>2+</sup> and EGTA was determined using MaxChelator (WEBMAXCLITE v1.15 <ext-link ext-link-type="uri" xlink:href="http://maxchelator.stanford.edu/webmaxc/webmaxclite115.htm">http://maxchelator.stanford.edu/webmaxc/webmaxclite115.htm</ext-link>). Following a 2 hr incubation at 36°C, reactions were filtered through Whatman GF/B Filters using a Brandel M24-R Harvester. [<sup>3</sup>H]ryanodine binding was determined using a Beckman LS6500 scintillation counter and BioSafe II scintillation cocktail (RPI Corp). Non-specific binding was quantified in the presence of 2 µM unlabeled ryanodine (MP Biomedicals) and subtracted.</p></sec><sec id="s4-8"><title>Quantitative real time PCR</title><p>Left atrial tissue of <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> and <italic>R26<sup>CreERT2</sup></italic> mice was removed two weeks after receiving tamoxifen and RNA was isolated using a Trizol (Invitrogen) based method. Reverse transcription reaction was carried out using the qScript cDNA synthesis kit (Quanta) according to the manufacturer’s protocol. Quantitative RT-PCR was performed using the Power SYBR Green PCR Master Mix (Applied Biosystems) and run on an Applied Biosystems AB7500 machine. Relative fold changes were calculated using the comparative threshold cycle method (2<sup>-ΔΔCt</sup>), using glyceraldehyde-3-phosphate dehydrogenase (<italic>Gapdh</italic>) gene expression level as internal control.</p></sec><sec id="s4-9"><title>PCR primers</title><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th valign="top">Gene</th><th valign="top">F primer</th><th valign="top">R primer</th></tr></thead><tbody><tr><td valign="top"><italic>Tbx5</italic></td><td valign="top">GGCATGGAAGGAATCAAGGT</td><td valign="top">CTAGGAAACATTCTCCTCCCTGC</td></tr><tr><td valign="top"><italic>Ryr2</italic></td><td valign="top">CAAATCCTTCTGCTGCCAAG</td><td valign="top">CGAGGATGAGATCCAGTTCC</td></tr><tr><td valign="top"><italic>Atp2a2</italic></td><td valign="top">CTGGTGATATAGTGGAAATTGCTG</td><td valign="top">GGTCAGGGACAGGGTCAGTA</td></tr><tr><td valign="top"><italic>Pln</italic></td><td valign="top">TTATGCCAGGACGGCAAAAG</td><td valign="top">CACTGTGACGATCACCGAAG</td></tr><tr><td valign="top"><italic>Sln</italic></td><td valign="top">CTGAGGTCCTTGGTAGCCTG</td><td valign="top">GGTGTGTCAGGCATTGTGAG</td></tr><tr><td valign="top"><italic>Cacna1c</italic></td><td valign="top">CTACAGAAACCCATGTGAGCAT</td><td valign="top">CAGCCACGTTGTCAGTGTTG</td></tr><tr><td valign="top"><italic>Ncx1</italic></td><td valign="top">TTCTCATACTCCTCGTCATCG</td><td valign="top">TTGAGGACACCTGTGGAGTG</td></tr><tr><td valign="top"><italic>Calm1</italic></td><td valign="top">TGGGAATGGTTACATCAGTGC</td><td valign="top">CGCCATCAATATCTGCTTCTCT</td></tr><tr><td valign="top"><italic>Calm2</italic></td><td valign="top">ACGGGGATGGGACAATAACAA</td><td valign="top">TGCTGCACTAATATAGCCATTGC</td></tr><tr><td valign="top"><italic>Calm3</italic></td><td valign="top">GATGGCACCATTACCACCAAG</td><td valign="top">CGCTGTCTGTATCCTTCATCTTT</td></tr></tbody></table></table-wrap></sec><sec id="s4-10"><title>Statistical analysis</title><p>Values are represented as mean ±standard error of the mean (±SEM). Statistical significance for quantitative metrics of APs, SERCA, NCX, SR load, I<sub>CaL</sub>, spark frequency, and [Ca<sup>2+</sup>]<sub>i</sub> transients were determined using hierarchical statistical methods (<xref ref-type="bibr" rid="bib42">Sikkel et al., 2017</xref>). Statistical significance for mRNA, and protein expression studies was determined using Student’s t-test. Statistical significance of the nifedipine effect on AP duration was determined using two-tailed paired t-test. A two-tailed Fisher’s exact test was used for statistical significance of count-based analysis of AF inducibility and EAD and DAD count. Statistical significance is designated as *p&lt;0.05, **p&lt;0.01, and ***p&lt;0.001.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Evangalia Kranias for providing the phospholamban knockout mice (NIH HL26057). The project described was supported by R01 HL126509 and HL114010, AHA Collaborative Sciences Award, R33 HL123857, and T32HL007381.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Software, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Data curation, Formal analysis, Investigation, Visualization, Writing—review and editing</p></fn><fn fn-type="con" id="con4"><p>Conceptualization, Data curation, Investigation, Visualization, Writing—review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Visualization, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Software, Formal analysis, Investigation, Visualization, Writing—review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Investigation, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con9"><p>Investigation, Writing—review and editing</p></fn><fn fn-type="con" id="con10"><p>Conceptualization, Data curation, Formal analysis, Writing—review and editing</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Data curation, Software, Formal analysis, Supervision, Investigation, Visualization, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Supervision, Investigation, Methodology, Writing—review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Formal analysis, Supervision, Investigation, Methodology, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Formal analysis, Supervision, Project administration, Writing—review and editing</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Resources, Software, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (#71737) of the University of Chicago. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Chicago. All surgery was performed under isoflurane anesthesia, and every effort was made to minimize suffering.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><object-id pub-id-type="doi">10.7554/eLife.41814.030</object-id><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-41814-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarado</surname> <given-names>FJ</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Valdivia</surname> <given-names>HH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Ablation of the cardiac ryanodine receptor phospho-site Ser2808 does not alter the adrenergic response or the progression to heart failure in mice. Elimination of the genetic background as critical variable</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>103</volume><fpage>40</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2017.01.001</pub-id><pub-id pub-id-type="pmid">28065668</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrade</surname> <given-names>J</given-names></name><name><surname>Khairy</surname> <given-names>P</given-names></name><name><surname>Dobrev</surname> <given-names>D</given-names></name><name><surname>Nattel</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms</article-title><source>Circulation Research</source><volume>114</volume><fpage>1453</fpage><lpage>1468</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.303211</pub-id><pub-id pub-id-type="pmid">24763464</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname> <given-names>T</given-names></name><name><surname>Hu</surname> <given-names>X</given-names></name><name><surname>Zheng</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>S</given-names></name><name><surname>Kong</surname> <given-names>J</given-names></name><name><surname>Cai</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Resveratrol protects against lipopolysaccharide-induced cardiac dysfunction by enhancing SERCA2a activity through promoting the phospholamban oligomerization</article-title><source>American Journal of Physiology-Heart and Circulatory Physiology</source><volume>311</volume><fpage>H1051</fpage><lpage>H1062</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00296.2016</pub-id><pub-id pub-id-type="pmid">27591219</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bers</surname> <given-names>DM</given-names></name><name><surname>Grandi</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Human atrial fibrillation: insights from computational electrophysiological models</article-title><source>Trends in Cardiovascular Medicine</source><volume>21</volume><fpage>145</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.tcm.2012.04.004</pub-id><pub-id pub-id-type="pmid">22732550</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhupathy</surname> <given-names>P</given-names></name><name><surname>Babu</surname> <given-names>GJ</given-names></name><name><surname>Periasamy</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Sarcolipin and phospholamban as regulators of cardiac sarcoplasmic reticulum Ca<sup>2+</sup> ATPase</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>42</volume><fpage>903</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2007.03.738</pub-id><pub-id pub-id-type="pmid">17442337</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blaustein</surname> <given-names>MP</given-names></name><name><surname>Lederer</surname> <given-names>WJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Sodium/calcium exchange: its physiological implications</article-title><source>Physiological Reviews</source><volume>79</volume><fpage>763</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1152/physrev.1999.79.3.763</pub-id><pub-id pub-id-type="pmid">10390518</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourfiss</surname> <given-names>M</given-names></name><name><surname>Te Riele</surname> <given-names>AS</given-names></name><name><surname>Mast</surname> <given-names>TP</given-names></name><name><surname>Cramer</surname> <given-names>MJ</given-names></name><name><surname>VAN DER Heijden</surname> <given-names>JF</given-names></name><name><surname>VAN Veen</surname> <given-names>TA</given-names></name><name><surname>Loh</surname> <given-names>P</given-names></name><name><surname>Dooijes</surname> <given-names>D</given-names></name><name><surname>Hauer</surname> <given-names>RN</given-names></name><name><surname>Velthuis</surname> <given-names>BK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Influence of Genotype on Structural Atrial Abnormalities and Atrial Fibrillation or Flutter in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy</article-title><source>Journal of Cardiovascular Electrophysiology</source><volume>27</volume><fpage>1420</fpage><lpage>1428</lpage><pub-id pub-id-type="doi">10.1111/jce.13094</pub-id><pub-id pub-id-type="pmid">27572111</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brundel</surname> <given-names>BJ</given-names></name><name><surname>van Gelder</surname> <given-names>IC</given-names></name><name><surname>Henning</surname> <given-names>RH</given-names></name><name><surname>Tuinenburg</surname> <given-names>AE</given-names></name><name><surname>Deelman</surname> <given-names>LE</given-names></name><name><surname>Tieleman</surname> <given-names>RG</given-names></name><name><surname>Grandjean</surname> <given-names>JG</given-names></name><name><surname>van Gilst</surname> <given-names>WH</given-names></name><name><surname>Crijns</surname> <given-names>HJ</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Gene expression of proteins influencing the calcium homeostasis in patients with persistent and paroxysmal atrial fibrillation</article-title><source>Cardiovascular Research</source><volume>42</volume><fpage>443</fpage><lpage>454</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(99)00045-0</pub-id><pub-id pub-id-type="pmid">10533580</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruneau</surname> <given-names>BG</given-names></name><name><surname>Nemer</surname> <given-names>G</given-names></name><name><surname>Schmitt</surname> <given-names>JP</given-names></name><name><surname>Charron</surname> <given-names>F</given-names></name><name><surname>Robitaille</surname> <given-names>L</given-names></name><name><surname>Caron</surname> <given-names>S</given-names></name><name><surname>Conner</surname> <given-names>DA</given-names></name><name><surname>Gessler</surname> <given-names>M</given-names></name><name><surname>Nemer</surname> <given-names>M</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name><name><surname>Seidman</surname> <given-names>JG</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease</article-title><source>Cell</source><volume>106</volume><fpage>709</fpage><lpage>721</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00493-7</pub-id><pub-id pub-id-type="pmid">11572777</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname> <given-names>E</given-names></name><name><surname>Chang</surname> <given-names>SL</given-names></name><name><surname>Hsiao</surname> <given-names>YW</given-names></name><name><surname>Singhal</surname> <given-names>R</given-names></name><name><surname>Liu</surname> <given-names>SH</given-names></name><name><surname>Leha</surname> <given-names>T</given-names></name><name><surname>Lin</surname> <given-names>WY</given-names></name><name><surname>Hsu</surname> <given-names>CP</given-names></name><name><surname>Chen</surname> <given-names>YC</given-names></name><name><surname>Chen</surname> <given-names>YJ</given-names></name><name><surname>Wu</surname> <given-names>TJ</given-names></name><name><surname>Higa</surname> <given-names>S</given-names></name><name><surname>Chen</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation</article-title><source>Heart Rhythm</source><volume>12</volume><fpage>1046</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2015.01.044</pub-id><pub-id pub-id-type="pmid">25640634</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christophersen</surname> <given-names>IE</given-names></name><name><surname>Ravn</surname> <given-names>LS</given-names></name><name><surname>Budtz-Joergensen</surname> <given-names>E</given-names></name><name><surname>Skytthe</surname> <given-names>A</given-names></name><name><surname>Haunsoe</surname> <given-names>S</given-names></name><name><surname>Svendsen</surname> <given-names>JH</given-names></name><name><surname>Christensen</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Familial aggregation of atrial fibrillation: a study in Danish twins</article-title><source>Circulation. Arrhythmia and electrophysiology</source><volume>2</volume><fpage>378</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1161/CIRCEP.108.786665</pub-id><pub-id pub-id-type="pmid">19808493</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Chang</surname> <given-names>Y</given-names></name><name><surname>Yuan</surname> <given-names>Q</given-names></name><name><surname>Ji</surname> <given-names>G</given-names></name><name><surname>Zhai</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Characterization of Ca<sup>2+</sup> handling proteins and contractile proteins in patients with lone atrial fibrillation</article-title><source>International Journal of Cardiology</source><volume>202</volume><fpage>749</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2015.10.010</pub-id><pub-id pub-id-type="pmid">26474465</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Pino</surname> <given-names>A</given-names></name><name><surname>Caruso</surname> <given-names>E</given-names></name><name><surname>Costanzo</surname> <given-names>L</given-names></name><name><surname>Guccione</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A novel RyR2 mutation in a 2-year-old baby presenting with atrial fibrillation, atrial flutter, and atrial ectopic tachycardia</article-title><source>Heart Rhythm</source><volume>11</volume><fpage>1480</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2014.04.037</pub-id><pub-id pub-id-type="pmid">24793461</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobrev</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Atrial Ca<sup>2+</sup> signaling in atrial fibrillation as an antiarrhythmic drug target</article-title><source>Naunyn-Schmiedeberg's Archives of Pharmacology</source><volume>381</volume><fpage>195</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1007/s00210-009-0457-1</pub-id><pub-id pub-id-type="pmid">19784635</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Armouche</surname> <given-names>A</given-names></name><name><surname>Boknik</surname> <given-names>P</given-names></name><name><surname>Eschenhagen</surname> <given-names>T</given-names></name><name><surname>Carrier</surname> <given-names>L</given-names></name><name><surname>Knaut</surname> <given-names>M</given-names></name><name><surname>Ravens</surname> <given-names>U</given-names></name><name><surname>Dobrev</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Molecular determinants of altered Ca<sup>2+</sup> handling in human chronic atrial fibrillation</article-title><source>Circulation</source><volume>114</volume><fpage>670</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.106.636845</pub-id><pub-id pub-id-type="pmid">16894034</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatkin</surname> <given-names>D</given-names></name><name><surname>Santiago</surname> <given-names>CF</given-names></name><name><surname>Huttner</surname> <given-names>IG</given-names></name><name><surname>Lubitz</surname> <given-names>SA</given-names></name><name><surname>Ellinor</surname> <given-names>PT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Genetics of Atrial Fibrillation: State of the Art in 2017</article-title><source>Heart, Lung and Circulation</source><volume>26</volume><fpage>894</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1016/j.hlc.2017.04.008</pub-id><pub-id pub-id-type="pmid">28601532</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Federico</surname> <given-names>M</given-names></name><name><surname>Portiansky</surname> <given-names>EL</given-names></name><name><surname>Sommese</surname> <given-names>L</given-names></name><name><surname>Alvarado</surname> <given-names>FJ</given-names></name><name><surname>Blanco</surname> <given-names>PG</given-names></name><name><surname>Zanuzzi</surname> <given-names>CN</given-names></name><name><surname>Dedman</surname> <given-names>J</given-names></name><name><surname>Kaetzel</surname> <given-names>M</given-names></name><name><surname>Wehrens</surname> <given-names>XHT</given-names></name><name><surname>Mattiazzi</surname> <given-names>A</given-names></name><name><surname>Palomeque</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Calcium-calmodulin-dependent protein kinase mediates the intracellular signalling pathways of cardiac apoptosis in mice with impaired glucose tolerance</article-title><source>The Journal of Physiology</source><volume>595</volume><fpage>4089</fpage><lpage>4108</lpage><pub-id pub-id-type="doi">10.1113/JP273714</pub-id><pub-id pub-id-type="pmid">28105734</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferrandi</surname> <given-names>M</given-names></name><name><surname>Barassi</surname> <given-names>P</given-names></name><name><surname>Tadini-Buoninsegni</surname> <given-names>F</given-names></name><name><surname>Bartolommei</surname> <given-names>G</given-names></name><name><surname>Molinari</surname> <given-names>I</given-names></name><name><surname>Tripodi</surname> <given-names>MG</given-names></name><name><surname>Reina</surname> <given-names>C</given-names></name><name><surname>Moncelli</surname> <given-names>MR</given-names></name><name><surname>Bianchi</surname> <given-names>G</given-names></name><name><surname>Ferrari</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition</article-title><source>British Journal of Pharmacology</source><volume>169</volume><fpage>1849</fpage><lpage>1861</lpage><pub-id pub-id-type="doi">10.1111/bph.12278</pub-id><pub-id pub-id-type="pmid">23763364</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname> <given-names>TH</given-names></name><name><surname>Herting</surname> <given-names>J</given-names></name><name><surname>Mason</surname> <given-names>FE</given-names></name><name><surname>Hartmann</surname> <given-names>N</given-names></name><name><surname>Watanabe</surname> <given-names>S</given-names></name><name><surname>Nikolaev</surname> <given-names>VO</given-names></name><name><surname>Sprenger</surname> <given-names>JU</given-names></name><name><surname>Fan</surname> <given-names>P</given-names></name><name><surname>Yao</surname> <given-names>L</given-names></name><name><surname>Popov</surname> <given-names>AF</given-names></name><name><surname>Danner</surname> <given-names>BC</given-names></name><name><surname>Schöndube</surname> <given-names>F</given-names></name><name><surname>Belardinelli</surname> <given-names>L</given-names></name><name><surname>Hasenfuss</surname> <given-names>G</given-names></name><name><surname>Maier</surname> <given-names>LS</given-names></name><name><surname>Sossalla</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Late INa increases diastolic SR Ca<sup>2+</sup>-leak in atrial myocardium by activating PKA and CaMKII</article-title><source>Cardiovascular Research</source><volume>107</volume><fpage>184</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvv153</pub-id><pub-id pub-id-type="pmid">25990311</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandi</surname> <given-names>E</given-names></name><name><surname>Pandit</surname> <given-names>SV</given-names></name><name><surname>Voigt</surname> <given-names>N</given-names></name><name><surname>Workman</surname> <given-names>AJ</given-names></name><name><surname>Dobrev</surname> <given-names>D</given-names></name><name><surname>Jalife</surname> <given-names>J</given-names></name><name><surname>Bers</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Human atrial action potential and Ca<sup>2+</sup> model: sinus rhythm and chronic atrial fibrillation</article-title><source>Circulation research</source><volume>109</volume><fpage>1055</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.253955</pub-id><pub-id pub-id-type="pmid">21921263</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greiser</surname> <given-names>M</given-names></name><name><surname>Lederer</surname> <given-names>WJ</given-names></name><name><surname>Schotten</surname> <given-names>U</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Alterations of atrial Ca<sup>2+</sup> handling as cause and consequence of atrial fibrillation</article-title><source>Cardiovascular Research</source><volume>89</volume><fpage>722</fpage><lpage>733</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvq389</pub-id><pub-id pub-id-type="pmid">21159669</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heijman</surname> <given-names>J</given-names></name><name><surname>Voigt</surname> <given-names>N</given-names></name><name><surname>Nattel</surname> <given-names>S</given-names></name><name><surname>Dobrev</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cellular and molecular electrophysiology of atrial fibrillation initiation, maintenance, and progression</article-title><source>Circulation Research</source><volume>114</volume><fpage>1483</fpage><lpage>1499</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.302226</pub-id><pub-id pub-id-type="pmid">24763466</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hove-Madsen</surname> <given-names>L</given-names></name><name><surname>Llach</surname> <given-names>A</given-names></name><name><surname>Bayes-Genís</surname> <given-names>A</given-names></name><name><surname>Roura</surname> <given-names>S</given-names></name><name><surname>Rodriguez Font</surname> <given-names>E</given-names></name><name><surname>Arís</surname> <given-names>A</given-names></name><name><surname>Cinca</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes</article-title><source>Circulation</source><volume>110</volume><fpage>1358</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000141296.59876.87</pub-id><pub-id pub-id-type="pmid">15313939</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jost</surname> <given-names>N</given-names></name><name><surname>Nagy</surname> <given-names>N</given-names></name><name><surname>Corici</surname> <given-names>C</given-names></name><name><surname>Kohajda</surname> <given-names>Z</given-names></name><name><surname>Horváth</surname> <given-names>A</given-names></name><name><surname>Acsai</surname> <given-names>K</given-names></name><name><surname>Biliczki</surname> <given-names>P</given-names></name><name><surname>Levijoki</surname> <given-names>J</given-names></name><name><surname>Pollesello</surname> <given-names>P</given-names></name><name><surname>Koskelainen</surname> <given-names>T</given-names></name><name><surname>Otsomaa</surname> <given-names>L</given-names></name><name><surname>Tóth</surname> <given-names>A</given-names></name><name><surname>Papp</surname> <given-names>JG</given-names></name><name><surname>Varró</surname> <given-names>A</given-names></name><name><surname>Virág</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ORM-10103, a novel specific inhibitor of the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger, decreases early and delayed afterdepolarizations in the canine heart</article-title><source>British Journal of Pharmacology</source><volume>170</volume><fpage>768</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1111/bph.12228</pub-id><pub-id pub-id-type="pmid">23647096</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname> <given-names>JH</given-names></name><name><surname>Zhang</surname> <given-names>Y</given-names></name><name><surname>Lei</surname> <given-names>M</given-names></name><name><surname>Grace</surname> <given-names>AA</given-names></name><name><surname>Huang</surname> <given-names>CL</given-names></name><name><surname>Fraser</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Atrial arrhythmia, triggering events and conduction abnormalities in isolated murine RyR2-P2328S hearts</article-title><source>Acta Physiologica</source><volume>207</volume><fpage>308</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1111/apha.12006</pub-id><pub-id pub-id-type="pmid">22958452</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kormos</surname> <given-names>A</given-names></name><name><surname>Nagy</surname> <given-names>N</given-names></name><name><surname>Acsai</surname> <given-names>K</given-names></name><name><surname>Váczi</surname> <given-names>K</given-names></name><name><surname>Ágoston</surname> <given-names>S</given-names></name><name><surname>Pollesello</surname> <given-names>P</given-names></name><name><surname>Levijoki</surname> <given-names>J</given-names></name><name><surname>Szentandrássy</surname> <given-names>N</given-names></name><name><surname>Papp</surname> <given-names>JG</given-names></name><name><surname>Varró</surname> <given-names>A</given-names></name><name><surname>Tóth</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Efficacy of selective NCX inhibition by ORM-10103 during simulated ischemia/reperfusion</article-title><source>European Journal of Pharmacology</source><volume>740</volume><fpage>539</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2014.06.033</pub-id><pub-id pub-id-type="pmid">24975099</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenaerts</surname> <given-names>I</given-names></name><name><surname>Bito</surname> <given-names>V</given-names></name><name><surname>Heinzel</surname> <given-names>FR</given-names></name><name><surname>Driesen</surname> <given-names>RB</given-names></name><name><surname>Holemans</surname> <given-names>P</given-names></name><name><surname>D'hooge</surname> <given-names>J</given-names></name><name><surname>Heidbüchel</surname> <given-names>H</given-names></name><name><surname>Sipido</surname> <given-names>KR</given-names></name><name><surname>Willems</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ultrastructural and functional remodeling of the coupling between Ca<sup>2+</sup> influx and sarcoplasmic reticulum Ca<sup>2+</sup> release in right atrial myocytes from experimental persistent atrial fibrillation</article-title><source>Circulation Research</source><volume>105</volume><fpage>876</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.206276</pub-id><pub-id pub-id-type="pmid">19762679</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>L</given-names></name><name><surname>Louch</surname> <given-names>WE</given-names></name><name><surname>Niederer</surname> <given-names>SA</given-names></name><name><surname>Andersson</surname> <given-names>KB</given-names></name><name><surname>Christensen</surname> <given-names>G</given-names></name><name><surname>Sejersted</surname> <given-names>OM</given-names></name><name><surname>Smith</surname> <given-names>NP</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Calcium dynamics in the ventricular myocytes of SERCA2 knockout mice: A modeling study</article-title><source>Biophysical Journal</source><volume>100</volume><fpage>322</fpage><lpage>331</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2010.11.048</pub-id><pub-id pub-id-type="pmid">21244828</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname> <given-names>X</given-names></name><name><surname>Xie</surname> <given-names>H</given-names></name><name><surname>Zhu</surname> <given-names>PH</given-names></name><name><surname>Hu</surname> <given-names>J</given-names></name><name><surname>Zhao</surname> <given-names>Q</given-names></name><name><surname>Wang</surname> <given-names>CS</given-names></name><name><surname>Yang</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Ryanodine receptor-mediated Ca<sup>2+</sup> events in atrial myocytes of patients with atrial fibrillation</article-title><source>Cardiology</source><volume>111</volume><fpage>102</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1159/000119697</pub-id><pub-id pub-id-type="pmid">18376121</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima-Leopoldo</surname> <given-names>AP</given-names></name><name><surname>Sugizaki</surname> <given-names>MM</given-names></name><name><surname>Leopoldo</surname> <given-names>AS</given-names></name><name><surname>Carvalho</surname> <given-names>RF</given-names></name><name><surname>Nogueira</surname> <given-names>CR</given-names></name><name><surname>Nascimento</surname> <given-names>AF</given-names></name><name><surname>Martinez</surname> <given-names>PF</given-names></name><name><surname>Luvizotto</surname> <given-names>RA</given-names></name><name><surname>Padovani</surname> <given-names>CR</given-names></name><name><surname>Cicogna</surname> <given-names>AC</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Obesity induces upregulation of genes involved in myocardial Ca<sup>2+</sup> handling</article-title><source>Brazilian Journal of Medical and Biological Research</source><volume>41</volume><fpage>615</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1590/S0100-879X2008000700011</pub-id><pub-id pub-id-type="pmid">18719744</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima-Leopoldo</surname> <given-names>AP</given-names></name><name><surname>Leopoldo</surname> <given-names>AS</given-names></name><name><surname>da Silva</surname> <given-names>DC</given-names></name><name><surname>do Nascimento</surname> <given-names>AF</given-names></name><name><surname>de Campos</surname> <given-names>DH</given-names></name><name><surname>Luvizotto</surname> <given-names>RA</given-names></name><name><surname>de Deus</surname> <given-names>AF</given-names></name><name><surname>Freire</surname> <given-names>PP</given-names></name><name><surname>Medeiros</surname> <given-names>A</given-names></name><name><surname>Okoshi</surname> <given-names>K</given-names></name><name><surname>Cicogna</surname> <given-names>AC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Long-term obesity promotes alterations in diastolic function induced by reduction of phospholamban phosphorylation at serine-16 without affecting calcium handling</article-title><source>Journal of Applied Physiology</source><volume>117</volume><fpage>669</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1152/japplphysiol.00088.2014</pub-id><pub-id pub-id-type="pmid">24970855</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lugenbiel</surname> <given-names>P</given-names></name><name><surname>Wenz</surname> <given-names>F</given-names></name><name><surname>Govorov</surname> <given-names>K</given-names></name><name><surname>Schweizer</surname> <given-names>PA</given-names></name><name><surname>Katus</surname> <given-names>HA</given-names></name><name><surname>Thomas</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Atrial fibrillation complicated by heart failure induces distinct remodeling of calcium cycling proteins</article-title><source>PLoS One</source><volume>10</volume><elocation-id>e0116395</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0116395</pub-id><pub-id pub-id-type="pmid">25775120</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname> <given-names>W</given-names></name><name><surname>Grupp</surname> <given-names>IL</given-names></name><name><surname>Harrer</surname> <given-names>J</given-names></name><name><surname>Ponniah</surname> <given-names>S</given-names></name><name><surname>Grupp</surname> <given-names>G</given-names></name><name><surname>Duffy</surname> <given-names>JJ</given-names></name><name><surname>Doetschman</surname> <given-names>T</given-names></name><name><surname>Kranias</surname> <given-names>EG</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation</article-title><source>Circulation Research</source><volume>75</volume><fpage>401</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1161/01.RES.75.3.401</pub-id><pub-id pub-id-type="pmid">8062415</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macquaide</surname> <given-names>N</given-names></name><name><surname>Tuan</surname> <given-names>HT</given-names></name><name><surname>Hotta</surname> <given-names>J</given-names></name><name><surname>Sempels</surname> <given-names>W</given-names></name><name><surname>Lenaerts</surname> <given-names>I</given-names></name><name><surname>Holemans</surname> <given-names>P</given-names></name><name><surname>Hofkens</surname> <given-names>J</given-names></name><name><surname>Jafri</surname> <given-names>MS</given-names></name><name><surname>Willems</surname> <given-names>R</given-names></name><name><surname>Sipido</surname> <given-names>KR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ryanodine receptor cluster fragmentation and redistribution in persistent atrial fibrillation enhance calcium release</article-title><source>Cardiovascular Research</source><volume>108</volume><fpage>387</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvv231</pub-id><pub-id pub-id-type="pmid">26490742</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDermott</surname> <given-names>DA</given-names></name><name><surname>Hatcher</surname> <given-names>CJ</given-names></name><name><surname>Basson</surname> <given-names>CT</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Atrial Fibrillation and Other Clinical Manifestations of Altered TBX5 Dosage in Typical Holt-Oram Syndrome</article-title><source>Circulation Research</source><volume>103</volume><elocation-id>e96</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.108.181834</pub-id><pub-id pub-id-type="pmid">18818409</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadadur</surname> <given-names>RD</given-names></name><name><surname>Broman</surname> <given-names>MT</given-names></name><name><surname>Boukens</surname> <given-names>B</given-names></name><name><surname>Mazurek</surname> <given-names>SR</given-names></name><name><surname>Yang</surname> <given-names>X</given-names></name><name><surname>van den Boogaard</surname> <given-names>M</given-names></name><name><surname>Bekeny</surname> <given-names>J</given-names></name><name><surname>Gadek</surname> <given-names>M</given-names></name><name><surname>Ward</surname> <given-names>T</given-names></name><name><surname>Zhang</surname> <given-names>M</given-names></name><name><surname>Qiao</surname> <given-names>Y</given-names></name><name><surname>Martin</surname> <given-names>JF</given-names></name><name><surname>Seidman</surname> <given-names>CE</given-names></name><name><surname>Seidman</surname> <given-names>J</given-names></name><name><surname>Christoffels</surname> <given-names>V</given-names></name><name><surname>Efimov</surname> <given-names>IR</given-names></name><name><surname>McNally</surname> <given-names>EM</given-names></name><name><surname>Weber</surname> <given-names>CR</given-names></name><name><surname>Moskowitz</surname> <given-names>IP</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Pitx2 modulates a Tbx5-dependent gene regulatory network to maintain atrial rhythm</article-title><source>Science Translational Medicine</source><volume>8</volume><elocation-id>ra115</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.aaf4891</pub-id><pub-id pub-id-type="pmid">27582060</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagy</surname> <given-names>N</given-names></name><name><surname>Kormos</surname> <given-names>A</given-names></name><name><surname>Kohajda</surname> <given-names>Z</given-names></name><name><surname>Szebeni</surname> <given-names>Á</given-names></name><name><surname>Szepesi</surname> <given-names>J</given-names></name><name><surname>Pollesello</surname> <given-names>P</given-names></name><name><surname>Levijoki</surname> <given-names>J</given-names></name><name><surname>Acsai</surname> <given-names>K</given-names></name><name><surname>Virág</surname> <given-names>L</given-names></name><name><surname>Nánási</surname> <given-names>PP</given-names></name><name><surname>Papp</surname> <given-names>JG</given-names></name><name><surname>Varró</surname> <given-names>A</given-names></name><name><surname>Tóth</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Selective Na<sup>+</sup>/Ca<sup>2+</sup> exchanger inhibition prevents Ca<sup>2+</sup> overload-induced triggered arrhythmias</article-title><source>British journal of pharmacology</source><volume>171</volume><fpage>5665</fpage><lpage>5681</lpage><pub-id pub-id-type="doi">10.1111/bph.12867</pub-id><pub-id pub-id-type="pmid">25073832</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neef</surname> <given-names>S</given-names></name><name><surname>Dybkova</surname> <given-names>N</given-names></name><name><surname>Sossalla</surname> <given-names>S</given-names></name><name><surname>Ort</surname> <given-names>KR</given-names></name><name><surname>Fluschnik</surname> <given-names>N</given-names></name><name><surname>Neumann</surname> <given-names>K</given-names></name><name><surname>Seipelt</surname> <given-names>R</given-names></name><name><surname>Schöndube</surname> <given-names>FA</given-names></name><name><surname>Hasenfuss</surname> <given-names>G</given-names></name><name><surname>Maier</surname> <given-names>LS</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>CaMKII-dependent diastolic SR Ca<sup>2+</sup> leak and elevated diastolic Ca<sup>2+</sup> levels in right atrial myocardium of patients with atrial fibrillation</article-title><source>Circulation Research</source><volume>106</volume><fpage>1134</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.203836</pub-id><pub-id pub-id-type="pmid">20056922</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishida</surname> <given-names>K</given-names></name><name><surname>Nattel</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Atrial fibrillation compendium: historical context and detailed translational perspective on an important clinical problem</article-title><source>Circulation research</source><volume>114</volume><fpage>1447</fpage><lpage>1452</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.303466</pub-id><pub-id pub-id-type="pmid">24763463</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parikh</surname> <given-names>A</given-names></name><name><surname>Mantravadi</surname> <given-names>R</given-names></name><name><surname>Kozhevnikov</surname> <given-names>D</given-names></name><name><surname>Roche</surname> <given-names>MA</given-names></name><name><surname>Ye</surname> <given-names>Y</given-names></name><name><surname>Owen</surname> <given-names>LJ</given-names></name><name><surname>Puglisi</surname> <given-names>JL</given-names></name><name><surname>Abramson</surname> <given-names>JJ</given-names></name><name><surname>Salama</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Ranolazine stabilizes cardiac ryanodine receptors: a novel mechanism for the suppression of early afterdepolarization and torsades de pointes in long QT type 2</article-title><source>Heart Rhythm</source><volume>9</volume><fpage>953</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1016/j.hrthm.2012.01.010</pub-id><pub-id pub-id-type="pmid">22245792</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanmugam</surname> <given-names>M</given-names></name><name><surname>Molina</surname> <given-names>CE</given-names></name><name><surname>Gao</surname> <given-names>S</given-names></name><name><surname>Severac-Bastide</surname> <given-names>R</given-names></name><name><surname>Fischmeister</surname> <given-names>R</given-names></name><name><surname>Babu</surname> <given-names>GJ</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Decreased sarcolipin protein expression and enhanced sarco(endo)plasmic reticulum Ca<sup>2+ </sup>uptake in human atrial fibrillation</article-title><source>Biochemical and Biophysical Research Communications</source><volume>410</volume><fpage>97</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2011.05.113</pub-id><pub-id pub-id-type="pmid">21640081</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sikkel</surname> <given-names>MB</given-names></name><name><surname>Francis</surname> <given-names>DP</given-names></name><name><surname>Howard</surname> <given-names>J</given-names></name><name><surname>Gordon</surname> <given-names>F</given-names></name><name><surname>Rowlands</surname> <given-names>C</given-names></name><name><surname>Peters</surname> <given-names>NS</given-names></name><name><surname>Lyon</surname> <given-names>AR</given-names></name><name><surname>Harding</surname> <given-names>SE</given-names></name><name><surname>MacLeod</surname> <given-names>KT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hierarchical statistical techniques are necessary to draw reliable conclusions from analysis of isolated cardiomyocyte studies</article-title><source>Cardiovascular Research</source><volume>113</volume><fpage>1743</fpage><lpage>1752</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvx151</pub-id><pub-id pub-id-type="pmid">29016722</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sinner</surname> <given-names>MF</given-names></name><name><surname>Tucker</surname> <given-names>NR</given-names></name><name><surname>Lunetta</surname> <given-names>KL</given-names></name><name><surname>Ozaki</surname> <given-names>K</given-names></name><name><surname>Smith</surname> <given-names>JG</given-names></name><name><surname>Trompet</surname> <given-names>S</given-names></name><name><surname>Bis</surname> <given-names>JC</given-names></name><name><surname>Lin</surname> <given-names>H</given-names></name><name><surname>Chung</surname> <given-names>MK</given-names></name><name><surname>Nielsen</surname> <given-names>JB</given-names></name><name><surname>Lubitz</surname> <given-names>SA</given-names></name><name><surname>Krijthe</surname> <given-names>BP</given-names></name><name><surname>Magnani</surname> <given-names>JW</given-names></name><name><surname>Ye</surname> <given-names>J</given-names></name><name><surname>Gollob</surname> <given-names>MH</given-names></name><name><surname>Tsunoda</surname> <given-names>T</given-names></name><name><surname>Müller-Nurasyid</surname> <given-names>M</given-names></name><name><surname>Lichtner</surname> <given-names>P</given-names></name><name><surname>Peters</surname> <given-names>A</given-names></name><name><surname>Dolmatova</surname> <given-names>E</given-names></name><name><surname>Kubo</surname> <given-names>M</given-names></name><name><surname>Smith</surname> <given-names>JD</given-names></name><name><surname>Psaty</surname> <given-names>BM</given-names></name><name><surname>Smith</surname> <given-names>NL</given-names></name><name><surname>Jukema</surname> <given-names>JW</given-names></name><name><surname>Chasman</surname> <given-names>DI</given-names></name><name><surname>Albert</surname> <given-names>CM</given-names></name><name><surname>Ebana</surname> <given-names>Y</given-names></name><name><surname>Furukawa</surname> <given-names>T</given-names></name><name><surname>Macfarlane</surname> <given-names>PW</given-names></name><name><surname>Harris</surname> <given-names>TB</given-names></name><name><surname>Darbar</surname> <given-names>D</given-names></name><name><surname>Dörr</surname> <given-names>M</given-names></name><name><surname>Holst</surname> <given-names>AG</given-names></name><name><surname>Svendsen</surname> <given-names>JH</given-names></name><name><surname>Hofman</surname> <given-names>A</given-names></name><name><surname>Uitterlinden</surname> <given-names>AG</given-names></name><name><surname>Gudnason</surname> <given-names>V</given-names></name><name><surname>Isobe</surname> <given-names>M</given-names></name><name><surname>Malik</surname> <given-names>R</given-names></name><name><surname>Dichgans</surname> <given-names>M</given-names></name><name><surname>Rosand</surname> <given-names>J</given-names></name><name><surname>Van Wagoner</surname> <given-names>DR</given-names></name><name><surname>Benjamin</surname> <given-names>EJ</given-names></name><name><surname>Milan</surname> <given-names>DJ</given-names></name><name><surname>Melander</surname> <given-names>O</given-names></name><name><surname>Heckbert</surname> <given-names>SR</given-names></name><name><surname>Ford</surname> <given-names>I</given-names></name><name><surname>Liu</surname> <given-names>Y</given-names></name><name><surname>Barnard</surname> <given-names>J</given-names></name><name><surname>Olesen</surname> <given-names>MS</given-names></name><name><surname>Stricker</surname> <given-names>BH</given-names></name><name><surname>Tanaka</surname> <given-names>T</given-names></name><name><surname>Kääb</surname> <given-names>S</given-names></name><name><surname>Ellinor</surname> <given-names>PT</given-names></name><collab>METASTROKE Consortium</collab><collab>AFGen Consortium</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation</article-title><source>Circulation</source><volume>130</volume><fpage>1225</fpage><lpage>1235</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.009892</pub-id><pub-id pub-id-type="pmid">25124494</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ventura</surname> <given-names>A</given-names></name><name><surname>Kirsch</surname> <given-names>DG</given-names></name><name><surname>McLaughlin</surname> <given-names>ME</given-names></name><name><surname>Tuveson</surname> <given-names>DA</given-names></name><name><surname>Grimm</surname> <given-names>J</given-names></name><name><surname>Lintault</surname> <given-names>L</given-names></name><name><surname>Newman</surname> <given-names>J</given-names></name><name><surname>Reczek</surname> <given-names>EE</given-names></name><name><surname>Weissleder</surname> <given-names>R</given-names></name><name><surname>Jacks</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Restoration of p53 function leads to tumour regression in vivo</article-title><source>Nature</source><volume>445</volume><fpage>661</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/nature05541</pub-id><pub-id pub-id-type="pmid">17251932</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vest</surname> <given-names>JA</given-names></name><name><surname>Wehrens</surname> <given-names>XH</given-names></name><name><surname>Reiken</surname> <given-names>SR</given-names></name><name><surname>Lehnart</surname> <given-names>SE</given-names></name><name><surname>Dobrev</surname> <given-names>D</given-names></name><name><surname>Chandra</surname> <given-names>P</given-names></name><name><surname>Danilo</surname> <given-names>P</given-names></name><name><surname>Ravens</surname> <given-names>U</given-names></name><name><surname>Rosen</surname> <given-names>MR</given-names></name><name><surname>Marks</surname> <given-names>AR</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Defective cardiac ryanodine receptor regulation during atrial fibrillation</article-title><source>Circulation</source><volume>111</volume><fpage>2025</fpage><lpage>2032</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000162461.67140.4C</pub-id><pub-id pub-id-type="pmid">15851612</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voigt</surname> <given-names>N</given-names></name><name><surname>Li</surname> <given-names>N</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Wang</surname> <given-names>W</given-names></name><name><surname>Trafford</surname> <given-names>AW</given-names></name><name><surname>Abu-Taha</surname> <given-names>I</given-names></name><name><surname>Sun</surname> <given-names>Q</given-names></name><name><surname>Wieland</surname> <given-names>T</given-names></name><name><surname>Ravens</surname> <given-names>U</given-names></name><name><surname>Nattel</surname> <given-names>S</given-names></name><name><surname>Wehrens</surname> <given-names>XH</given-names></name><name><surname>Dobrev</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Enhanced sarcoplasmic reticulum Ca<sup>2+</sup> leak and increased Na<sup>+</sup>-Ca<sup>2+</sup> exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation</article-title><source>Circulation</source><volume>125</volume><fpage>2059</fpage><lpage>2070</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.111.067306</pub-id><pub-id pub-id-type="pmid">22456474</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Voigt</surname> <given-names>N</given-names></name><name><surname>Heijman</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>Q</given-names></name><name><surname>Chiang</surname> <given-names>DY</given-names></name><name><surname>Li</surname> <given-names>N</given-names></name><name><surname>Karck</surname> <given-names>M</given-names></name><name><surname>Wehrens</surname> <given-names>XHT</given-names></name><name><surname>Nattel</surname> <given-names>S</given-names></name><name><surname>Dobrev</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation</article-title><source>Circulation</source><volume>129</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.006641</pub-id><pub-id pub-id-type="pmid">24249718</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weng</surname> <given-names>LC</given-names></name><name><surname>Preis</surname> <given-names>SR</given-names></name><name><surname>Hulme</surname> <given-names>OL</given-names></name><name><surname>Larson</surname> <given-names>MG</given-names></name><name><surname>Choi</surname> <given-names>SH</given-names></name><name><surname>Wang</surname> <given-names>B</given-names></name><name><surname>Trinquart</surname> <given-names>L</given-names></name><name><surname>McManus</surname> <given-names>DD</given-names></name><name><surname>Staerk</surname> <given-names>L</given-names></name><name><surname>Lin</surname> <given-names>H</given-names></name><name><surname>Lunetta</surname> <given-names>KL</given-names></name><name><surname>Ellinor</surname> <given-names>PT</given-names></name><name><surname>Benjamin</surname> <given-names>EJ</given-names></name><name><surname>Lubitz</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Genetic Predisposition, Clinical Risk Factor Burden, and Lifetime Risk of Atrial Fibrillation</article-title><source>Circulation</source><volume>137</volume><fpage>1027</fpage><lpage>1038</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.117.031431</pub-id><pub-id pub-id-type="pmid">29129827</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>L</given-names></name><name><surname>Eu</surname> <given-names>JP</given-names></name><name><surname>Meissner</surname> <given-names>G</given-names></name><name><surname>Stamler</surname> <given-names>JS</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation</article-title><source>Science</source><volume>279</volume><fpage>234</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1126/science.279.5348.234</pub-id><pub-id pub-id-type="pmid">9422697</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>XH</given-names></name><name><surname>Nadadur</surname> <given-names>RD</given-names></name><name><surname>Hilvering</surname> <given-names>CR</given-names></name><name><surname>Bianchi</surname> <given-names>V</given-names></name><name><surname>Werner</surname> <given-names>M</given-names></name><name><surname>Mazurek</surname> <given-names>SR</given-names></name><name><surname>Gadek</surname> <given-names>M</given-names></name><name><surname>Shen</surname> <given-names>KM</given-names></name><name><surname>Goldman</surname> <given-names>JA</given-names></name><name><surname>Tyan</surname> <given-names>L</given-names></name><name><surname>Bekeny</surname> <given-names>J</given-names></name><name><surname>Hall</surname> <given-names>JM</given-names></name><name><surname>Lee</surname> <given-names>N</given-names></name><name><surname>Perez-Cervantes</surname> <given-names>C</given-names></name><name><surname>Burnicka-Turek</surname> <given-names>O</given-names></name><name><surname>Poss</surname> <given-names>KD</given-names></name><name><surname>Weber</surname> <given-names>CR</given-names></name><name><surname>de Laat</surname> <given-names>W</given-names></name><name><surname>Ruthenburg</surname> <given-names>AJ</given-names></name><name><surname>Moskowitz</surname> <given-names>IP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transcription-factor-dependent enhancer transcription defines a gene regulatory network for cardiac rhythm</article-title><source>eLife</source><volume>6</volume><elocation-id>e31683</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.31683</pub-id><pub-id pub-id-type="pmid">29280435</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaman</surname> <given-names>JA</given-names></name><name><surname>Harling</surname> <given-names>L</given-names></name><name><surname>Ashrafian</surname> <given-names>H</given-names></name><name><surname>Darzi</surname> <given-names>A</given-names></name><name><surname>Gooderham</surname> <given-names>N</given-names></name><name><surname>Athanasiou</surname> <given-names>T</given-names></name><name><surname>Peters</surname> <given-names>NS</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Post-operative atrial fibrillation is associated with a pre-existing structural and electrical substrate in human right atrial myocardium</article-title><source>International Journal of Cardiology</source><volume>220</volume><fpage>580</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1016/j.ijcard.2016.06.249</pub-id><pub-id pub-id-type="pmid">27390994</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.41814.031</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Lewis</surname><given-names>Richard S</given-names></name><role>Reviewing Editor</role><aff><institution>Stanford University School of Medicine</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Kass</surname><given-names>Robert S</given-names></name><role>Reviewer</role><aff><institution>Columbia University</institution><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Eisner</surname><given-names>David</given-names> </name><role>Reviewer</role><aff><institution>U. Manchester</institution><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;A calcium transport mechanism for atrial fibrillation in Tbx5 mutant mice&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Richard Aldrich as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Robert S. Kass (Reviewer #1); David Eisner (Reviewer #3).</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission. Our goal is to provide the essential revision requirements as a single set of instructions, so that you have a clear view of the revisions that are necessary for us to publish your work.</p><p>Summary:</p><p>This is an interesting study of the effects of the T-box transcription factor TBX5 on the susceptibility to atrial fibrillation (AF), the most common and difficult to treat human cardiac arrhythmia. The authors provide convincing evidence that knockout of <italic>Tbx5</italic> in adult mice leads to (1) decreased expression of the SR Ca<sup>2+</sup> pump SERCA2 and increased expression of phospholamban, leading to a decreased level of SR Ca<sup>2+</sup> loading; and (2) increased Na-Ca exchanger (NCX1) expression and activity, providing a mechanism for prolonged action potentials and triggered activity. Additional knockout of phospholamban restored normal SR loading and action potential duration and prevented triggered activity and AF in <italic>Tbx5</italic>-knockout mice. These results provide a mechanistic link from genetic (GWAS) studies to the cellular mechanisms of AF.</p><p>Essential revisions:</p><p>The reviewers all found the paper to be interesting and important, but raised a number of concerns that must be adequately addressed before it can be accepted. Some of the required revisions will require further experimentation within the framework of the presented studies and techniques.</p><p>1) In Figure 2, the AP is lengthened in the <italic>Tbx5</italic> KO cells, and the effect of nifedipine to shorten the AP is greatly increased. The authors interpret this as an effect of prolonged and increased NCX current, but a change in Ca<sub>v</sub>1.2 activity may also contribute. Ca<sub>v</sub>1.2 channels could be more active in the KO cells if there is less Ca<sup>2+</sup>-dependent inactivation due to less CICR (from the reduced SR Ca content). This could contribute to the prolonged APD and to a more pronounced effect of nifedipine in blocking these channels. To address this point, the authors should conduct voltage clamp recordings of the Ca<sub>v</sub>1.2 current to monitor the degree of inactivation in WT vs. KO, with and without nifedipine. Simultaneous measurement of [Ca<sup>2+</sup>]<sub>i</sub> would help establish a basis for these effects.</p><p>2) The authors suggest that a larger NCX current occurs in the <italic>Tbx5</italic> KO cells because of an increased NCX and decreased SERCA, but this needs some qualification. In the steady state, the amount of Ca pumped out of the cell must balance influx through L-type channels (assuming negligible PMCA activity). Thus, changes in SERCA and NCX cannot affect the integral of the NCX current. If the long plateau of the action potential in Figure 2B reflects an increase of delayed NCX current (due to prolongation of the Ca<sup>2+</sup> transient by decreased SERCA), then this must be associated with a decrease of NCX in the earlier stage of the action potential. Is there any evidence for this? As suggested above (#1), simultaneous recording of the action potential and [Ca<sup>2+</sup>]<sub>i</sub> in control and <italic>Tbx5</italic> KO cells would help to clarify this point.</p><p>3) In Figure 4E, the lack of effect of <italic>Tbx5</italic> KO on the amplitude of the twitch Ca<sup>2+</sup> transient is interesting given that SR Ca<sup>2+</sup> content is decreased. Two potential compensatory mechanisms should be addressed. 1) It may be a consequence of the prolongation of the AP. Stimulation of the cells with constant-duration square voltage clamp pulses while measuring [Ca<sup>2+</sup>]<sub>i</sub> (see #1 above) would show whether the Ca transient is now less in <italic>Tbx5</italic> than control. 2) It looks as though, as a consequence of the slowing of decay of the Ca<sup>2+</sup> transient (Figure 4F), the diastolic [Ca<sup>2+</sup>]<sub>i</sub> is elevated. This may reduce cytoplasmic Ca<sup>2+</sup> buffering such that a smaller total release of Ca<sup>2+</sup> from the SR could result in an unchanged amplitude of the Ca<sup>2+</sup> transient. Please comment on this possibility.</p><p>4) The statistical analysis may need to be modified. In Figure 1, please state the actual numbers of animals used in each group and for the t test. In Figure 2, 3C, 4E-I, and 5C-F, unless each myocyte comes from a different heart, it is invalid to use the number of cells as the &quot;n&quot; values for the t test (see Lazic, BMC Neurosci 2010;11:5). Either use hierarchical or nested statistical approaches (e.g., Sikkel, Francis and Howard, et al. 2017) or simply average cells from the same heart and reduce n to be the number of hearts.</p><p>5) Although PLB mRNA is increased in <italic>Tbx5</italic> KO mice, the functional contribution of PLB needs to be addressed by examining the phosphorylation status of PLB16 and PLB17.</p><p>6) The role of increased NCX in causing AF in <italic>Tbx5</italic>-KO mice needs to be tested directly. Can an NCX inhibitor eliminate EADs and DADs in <italic>Tbx5</italic>-KO myocytes?</p><p>7) The atrial phenotype of the <italic>Tbx5</italic> KO mouse (reduced RyR expression, increased NCX, reduced SERCA activity and SR Ca<sup>2+</sup> load) are typical heart failure phenotypes. This raises the question of whether the observed phenotype indicates the underlying basis of AF, or is secondary to ventricular changes leading to heart failure. This question may be addressed using the mouse model before it has progressed to the heart failure stage.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.41814.032</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>The reviewers all found the paper to be interesting and important, but raised a number of concerns that must be adequately addressed before it can be accepted. Some of the required revisions will require further experimentation within the framework of the presented studies and techniques.</p><p>1) In Figure 2, the AP is lengthened in the Tbx5 KO cells, and the effect of nifedipine to shorten the AP is greatly increased. The authors interpret this as an effect of prolonged and increased NCX current, but a change in Ca<sub>v</sub>1.2 activity may also contribute. Ca<sub>v</sub>1.2 channels could be more active in the KO cells if there is less Ca<sup>2+</sup>-dependent inactivation due to less CICR (from the reduced SR Ca content). This could contribute to the prolonged APD and to a more pronounced effect of nifedipine in blocking these channels. To address this point, the authors should conduct voltage clamp recordings of the Ca<sub>v</sub>1.2 current to monitor the degree of inactivation in WT vs. KO, with and without nifedipine. Simultaneous measurement of [Ca<sup>2+</sup>]<sub>i</sub> would help establish a basis for these effects.</p></disp-quote><p>We agree with the reviewers that I<sub>CaL</sub> could contribute to APD prolongation, and that calcium influx and efflux must be balanced. To address this, we have measured I<sub>CaL.</sub> We find peak I<sub>CaL</sub> is increased 92 ± 34% in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes in comparison to the <italic>R26<sup>CreERT2</sup></italic> control. (new Figure 2E-G). Additionally, 30 μM nifedipine completely blocked I<sub>Ca,L</sub> and eliminated any [Ca<sup>2+</sup>]<sub>i</sub> transient in both TBX5 KO and control cardiomyocytes (new Figure 2—figure supplement 1). These data are consistent with a role of I<sub>CaL</sub> in AP prolongation. Increased I<sub>CaL</sub> may augment peak [Ca]<sub>i</sub> in the setting of depressed SR load (Figure 4G) and also approximately balances the increase in NCX mediated calcium efflux (Figure 4I). We have added these observations to the Results and Discussion sections of the text.</p><disp-quote content-type="editor-comment"><p>2) The authors suggest that a larger NCX current occurs in the Tbx5 KO cells because of an increased NCX and decreased SERCA, but this needs some qualification. In the steady state, the amount of Ca pumped out of the cell must balance influx through L-type channels (assuming negligible PMCA activity). Thus, changes in SERCA and NCX cannot affect the integral of the NCX current. If the long plateau of the action potential in Figure 2B reflects an increase of delayed NCX current (due to prolongation of the Ca<sup>2+</sup> transient by decreased SERCA), then this must be associated with a decrease of NCX in the earlier stage of the action potential. Is there any evidence for this? As suggested above (#1), simultaneous recording of the action potential and [Ca<sup>2+</sup>]<sub>i</sub> in control and Tbx5 KO cells would help to clarify this point.</p></disp-quote><p>The reviewers correctly point out that calcium influx must match calcium efflux in steady state. We have now considered this point in the context of new experiments to determine I<sub>CaL.</sub> Our new finding that increased NCX current is offset by increased I<sub>CaL</sub> now can explain steady state [Ca]<sub>i</sub> balance. We have included these data (Figure 1 and 2) and include corresponding discussions. Nevertheless, the reviewers also point out that a decrease in NCX in the earlier stage of the action potential could also contribute to steady state [Ca]<sub>i</sub> balance. Indeed, in the setting of AP prolongation, a decreased electrochemical drive for inward I<sub>NCX</sub> could exist in the early part of the AP. Therefore, as suggested by the reviewers, simultaneous AP and [Ca<sup>2+</sup>]<sub>i</sub> measurements were performed (new Figure 1C). Peak [Ca]<sub>i</sub> was not depressed during the AP, consistent with our field stimulation experiments in Figure 4E. Thus, assuming that submembrane calcium in the vicinity of the NCX is also similar, then the electrochemical drive for inward I<sub>NCX</sub> may be decreased in the early part of the AP in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes relative to <italic>R26<sup>CreERT2</sup></italic> control. However, in the context of increased I<sub>CaL</sub> and I<sub>NCX</sub> activity, it is challenging to dissect the individual contributions of calcium-dependent currents at depolarized potentials. In the future we hope to better quantify the influx and efflux pathways for calcium during the AP with <italic>Tbx5</italic> deficiency using a combined experimental and computer modeling approach. A discussion of this point has been added to the manuscript.</p><disp-quote content-type="editor-comment"><p>3) In Figure 4E, the lack of effect of Tbx5 KO on the amplitude of the twitch Ca<sup>2+</sup> transient is interesting given that SR Ca<sup>2+</sup> content is decreased. Two potential compensatory mechanisms should be addressed. 1) It may be a consequence of the prolongation of the AP. Stimulation of the cells with constant-duration square voltage clamp pulses while measuring [Ca<sup>2+</sup>]<sub>i</sub> (see #1 above) would show whether the Ca transient is now less in Tbx5 than control. 2) It looks as though, as a consequence of the slowing of decay of the Ca<sup>2+</sup> transient (Figure 4F), the diastolic [Ca<sup>2+</sup>]<sub>i</sub> is elevated. This may reduce cytoplasmic Ca<sup>2+</sup> buffering such that a smaller total release of Ca<sup>2+</sup> from the SR could result in an unchanged amplitude of the Ca<sup>2+</sup> transient. Please comment on this possibility.</p></disp-quote><p>The new square wave experiment proposed by the reviewers is a very good idea because it allows us to assess the peak [Ca]<sub>i</sub> without the effect of AP prolongation. The square wave experiments are now shown in Figure 4—figure supplement 1. In these experiments <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> cardiomyocytes have a 23 ± 4% decrease in the calcium transient amplitude compared to controls. Our results suggest that AP duration (possibly coupled with increased I<sub>CaL</sub> density) can explain the similarities in peak twitch calcium between <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic> and <italic>R26<sup>CreERT2</sup></italic> cardiomyocytes(Figure 4E). It is also interesting to consider that altered buffering capacity could play a role. However, we did not detect any changes in rate of rise of the first 10 ms of the calcium transient as would be expected if a greater portion of calcium buffer was bound or if total calcium buffering capacity was altered. (<italic>R26<sup>CreERT2</sup></italic>riseslope = 107 ± 11 F/F<sub>o</sub>*s; <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>riseslope = 108 ± 18 F/F<sub>o</sub>*s, p=0.96). Furthermore, we want to emphasize that F<sub>o</sub> was always recorded at rest without pacing, so measurements of SR load would be unaffected by this possibility. This new data has been added to the manuscript.</p><disp-quote content-type="editor-comment"><p>4) The statistical analysis may need to be modified. In Figure 1, please state the actual numbers of animals used in each group and for the t test. In Figure 2, 3C, 4E-I, and 5C-F, unless each myocyte comes from a different heart, it is invalid to use the number of cells as the &quot;n&quot; values for the t test (see Lazic, BMC Neurosci 2010;11:5). Either use hierarchical or nested statistical approaches (e.g., Sikkel, Francis and Howard, 2017) or simply average cells from the same heart and reduce n to be the number of hearts.</p></disp-quote><p>As suggested, we adjusted the statistical analysis using the hierarchical approach described in Sikkel et al [1]. Animal numbers are stated in the text where applicable and all of the figures are corrected to show significance indicators based on the revised analysis.</p><disp-quote content-type="editor-comment"><p>5) Although PLB mRNA is increased in Tbx5 KO mice, the functional contribution of PLB needs to be addressed by examining the phosphorylation status of PLB16 and PLB17.</p></disp-quote><p>We agree that the phosphorylation status of PLN is important. Thus, we performed western blot for PLN-S16 and PLN-T17 in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>and <italic>R26<sup>CreERT2</sup></italic> control atria. Phosphorylation of PLN-S16 was significantly increased while that of PLN-T17 was unchanged in <italic>Tbx5<sup>fl/fl</sup>;R26<sup>CreERT2</sup></italic>compared to <italic>R26<sup>CreERT2</sup></italic> control (Figure 5a). Increased S16 phosphorylation may be a compensatory mechanism for the decrease in SERCA expression. However, based on measurements of SERCA expression and activity (Figure 4A, H), functional effects of PLN phosphorylation are not sufficient to normalize SERCA activity, but knockout of <italic>Pln</italic> is sufficient (Figure 5). This data and related discussion have been added to the manuscript.</p><disp-quote content-type="editor-comment"><p>6) The role of increased NCX in causing AF in Tbx5-KO mice needs to be tested directly. Can an NCX inhibitor eliminate EADs and DADs in Tbx5-KO myocytes?</p></disp-quote><p>As suggested by the reviewers, NCX inhibitors could theoretically reduce the frequency of DADs in our model. In our recordings using a new generation NCX inhibitor, ORM-10103, at 5μM, we observed a tendency towards action potential shortening (not significant) but no effect on frequency of triggered activity (EADs and DADs). A representative trace is shown in <xref ref-type="fig" rid="respfig1">Author response image 1A</xref>. However, very large I<sub>NCX</sub> is still detectable in the presence of 5µM ORM-10103 using a square wave voltage clamp pulse to trigger SR release, as described in point 3 (<xref ref-type="fig" rid="respfig1">Author response image 1B</xref>). I<sub>NCX</sub> inhibition was statistically insignificant (-4% ± 2%). Higher dosages of ORM-10103 or other NCX inhibitors are known to have off-target effects on Na<sup>+</sup>, Ca<sup>2+</sup> and K<sup>+</sup> channels, which would complicate interpretation [2,3], particularly in the setting of only partial NCX inhibition. Thus, it is unfortunately challenging to reach any conclusions from the NCX inhibitor data. As newer agents become available it would be reasonable to test their ability to inhibit triggered activity and AF in this model, and we address this in the Discussion.</p><p><xref ref-type="fig" rid="respfig1">Author response image 1</xref>&gt;</p><fig id="respfig1"><label>Author response image 1.</label><caption><title>ORM-10103 does not reduce the frequency of DADs.</title><p>(<bold>A</bold>) Simultaneous E<sub>m</sub>/[Ca]<sub>i</sub> recordings demonstrate prolonged APs and presence of DADs (one highlighted in inset). (<bold>B</bold>) Tail currents recorded after 40 ms square wave voltage clamp pulses reveal uninhibited I<sub>NCX</sub>.</p></caption><graphic mime-subtype="jpeg" mimetype="image" xlink:href="elife-41814-resp-fig1-v1"/></fig><disp-quote content-type="editor-comment"><p>7) The atrial phenotype of the Tbx5 KO mouse (reduced RyR expression, increased NCX, reduced SERCA activity and SR Ca<sup>2+</sup> load) are typical heart failure phenotypes. This raises the question of whether the observed phenotype indicates the underlying basis of AF, or is secondary to ventricular changes leading to heart failure. This question may be addressed using the mouse model before it has progressed to the heart failure stage.</p></disp-quote><p>It is true that heart failure could complicate our interpretations. However, all experiments were performed at 2 weeks following tamoxifen injection. At this time point, the mice do not have any changes in ejection fraction, which begins after 3 weeks post-tamoxifen treatment [4].</p><p>References:</p><p>1) Sikkel MB, Francis DP, Howard J, et al. Hierarchical statistical techniques are necessary to draw reliable conclusions from analysis of isolated cardiomyocyte studies. Cardiovascular research. Dec 1 2017;113(14):1743-1752.</p><p>2) Jost N, Nagy N, Corici C, et al. ORM-10103, a novel specific inhibitor of the Na+/Ca<sup>2+</sup> exchanger, decreases early and delayed afterdepolarizations in the canine heart. British journal of pharmacology. Oct 2013;170(4):768-778.</p><p>3) Amran MS, Homma N, Hashimoto K. Pharmacology of KB-R7943: a Na+-Ca<sup>2+</sup> exchange inhibitor. Cardiovascular drug reviews. Winter 2003;21(4):255-276.</p><p>4) Nadadur RD, Broman MT, Boukens B, et al. Pitx2 modulates a Tbx5-dependent gene regulatory network to maintain atrial rhythm. Science translational medicine. Aug 31 2016;8(354):354ra115.</p></body></sub-article></article>